Results for tag: chemotherapy
Total Items Found: 80
Judith Paice, PhD, RN, on Neuropathic Pain
Type of Page:TapVideo
Edit This Item
Tags for this item:
2015 Palliative Care in Oncology
Judith Paice
Northwestern University
neuropathic pain
postsurgical syndromes
chemotherapy
neurotoxicity
graft vs host disease
peripheral neuropathy
pain assessment
quality of life
adjuvant analgesics
antidepressant agents
opioids
anesthetics
interventional
nonpharmacological techniques
Created: 1/31/2016 12:21:36 AM
Order By Item Count
Order Alphabetically
-
16 gene recurrence score (1)
-
177Lu-DOTATATE (1)
-
17p deletion (1)
-
18F-fluciclovine PET/CT (1)
-
2015 Palliative Care in Oncology (16)
-
2016 ASTRO Annual Meeting (16)
-
2016 GI Cancers Symposium (15)
-
2016 NCCN Annual Meeting (21)
-
2016 NCCN Annual Meetng (1)
-
2016 NCCN guidelines (1)
-
2016 Palliative Care in Oncology (16)
-
2016 Quality Care Symposium (17)
-
2016 Survivorship Symposium (14)
-
2017 Cancer Survivorship Symposi (1)
-
2017 Quality Care Symposium (1)
-
2017 San Antonio Breast Cancer S (1)
-
21 gene score (1)
-
21-gene recurrence score (1)
-
21st Annual NCCN Conference (1)
-
3-D conformal radiation (1)
-
4R model (1)
-
5-fluorouracil (1)
-
5FU (1)
-
5-FU (1)
-
5HT3 antagonist (1)
-
5HT3 receptor (1)
-
7+3 chemotherapy (1)
-
A. Collier Smyth (1)
-
A. Craig Lockhart (2)
-
A. Kate Macdougall (4)
-
A. Oliver Sartor (5)
-
aacr 2020 (10)
-
AACR Covid and Cancer (7)
-
aacr virtual annual meeting (1)
-
AACR Virtual II (12)
-
Aakash Desai (1)
-
Aaksh Desai (2)
-
Aalaa Mahmoud (1)
-
Aaron Martin (1)
-
Aaron Sasson (1)
-
AARON TALLENT (2)
-
Abby B. Sandler (1)
-
Abby Rosenberg (1)
-
ABCSG trial (1)
-
ABCSG-16 trial (1)
-
ABCSG-18 (1)
-
ABCSG-18 trial (1)
-
abemaciclib (3)
-
abiraterone (9)
-
abiraterone acetate (6)
-
ablation (1)
-
Abramson Cancer Center (3)
-
abscopal responses (1)
-
ABVD chemotherapy (1)
-
AC (2)
-
aca (2)
-
academic cancer center (1)
-
academic health centers (1)
-
academic hospital (1)
-
acalabrutinib (1)
-
acalabrutinib, asco 2019, chronic lymphocytic leukemia, cll, obinutuzumab (1)
-
ACCC (5)
-
accelerate treatment (1)
-
accelerated fractionation radiot (1)
-
access (2)
-
access to care (2)
-
access to opioids (1)
-
ACCORD12 trial (2)
-
ACCRU trial (1)
-
ace-536 (1)
-
activated RAS (1)
-
active cancer surveillance (1)
-
active surveillance (1)
-
active symptom control (1)
-
active treatment (1)
-
ACTIVE8 trial (1)
-
acts-cc 02 trial (1)
-
acupuncture (2)
-
acute care (1)
-
acute lymphoblastic leukemia (8)
-
acute lymphocytic leukemia (1)
-
acute myeloblastic leukemia (1)
-
acute myeloid leukemia (14)
-
acute toxicity (1)
-
Adam Brufsky (1)
-
Adam Hayden (1)
-
Adam Metwalli (1)
-
Adam Stern (1)
-
Adam Sutton (1)
-
ADAPT trial (1)
-
adc (1)
-
adcs (1)
-
adenocarcinoma (4)
-
adipocytic sarcoma (1)
-
adipokines (1)
-
adjustment disorders (1)
-
adjuvant (10)
-
adjuvant analgesics (1)
-
adjuvant chemotherapy (11)
-
adjuvant docetaxel (1)
-
adjuvant endocrine therapy (3)
-
adjuvant endocrine treatment (1)
-
adjuvant endorcine therapy (1)
-
adjuvant hipec (1)
-
adjuvant radiotherapy (2)
-
adjuvant therapy (6)
-
adjuvant treatment (3)
-
adolescent cancer (1)
-
adolescent cancer survivor (1)
-
adolescent oncology (1)
-
adolescent survivor (1)
-
adolescents (1)
-
Adolfo González Serrano (1)
-
adoptive cell therapy (1)
-
ado-trastuzumab emtansine (1)
-
adriamycin (1)
-
Adrienne Boissy (1)
-
Adrienne R. Boissy (1)
-
Adrienne Scheck (1)
-
ADT (9)
-
adult ALL (1)
-
adult cancer (1)
-
advance care planning (1)
-
advance of the year (1)
-
advanced bladder cancer (1)
-
advanced breast cancer (7)
-
advanced cancer (9)
-
advanced cancer care (1)
-
advanced colorectal cancer (1)
-
advanced disease (3)
-
advanced lung cancer (3)
-
advanced lymphoma (1)
-
advanced melanoma (2)
-
advanced NSCLC (2)
-
advanced phase leukemia (1)
-
advanced practice nurse (1)
-
advanced prostate cancer (1)
-
advanced refractory cancer (1)
-
advanced solid tumor (1)
-
advanced urothelial carcinoma (1)
-
advanced-stage disease (1)
-
advances in therapy (1)
-
adverse events (9)
-
advocacy (1)
-
advocate (1)
-
aethera trial (1)
-
afatinib (6)
-
affordability (2)
-
affordability of care (1)
-
affordable care (1)
-
Affordable Care Act (3)
-
affordable drug initiative (1)
-
African American (2)
-
African Americans (1)
-
age 40 (1)
-
age 50 (1)
-
agent-based therapy (2)
-
aggressive lymphomas (1)
-
aggressive medical care (1)
-
aggressive myeloma (1)
-
aggressive therapy (1)
-
aggressive treatment (2)
-
aging population (1)
-
agnostic therapy (1)
-
AHCT (3)
-
AHMED ELHAJ (1)
-
AI (1)
-
Aichi Cancer Center Hospital (1)
-
AIO trial (1)
-
Aix Marseille University (2)
-
Ajay Nooka (2)
-
Ajeet Gajra (1)
-
Aju Mathew (1)
-
Akila Viswanathan (1)
-
akt1 mutation (1)
-
akt3 (1)
-
Al Benson (3)
-
Alain Ravaud (2)
-
alan f. list (8)
-
Alan List (2)
-
Alan Pollack (1)
-
Alan Venook (2)
-
Albert Deisseroth (1)
-
Alcala de Henares University (1)
-
ALCHEMIST (1)
-
ALCYONE trial (1)
-
Alec Kupelian (1)
-
alectinib (3)
-
Aleix Prat (2)
-
Alejandro Chaoul (1)
-
Alejandro Salicrup (1)
-
ALESIA (1)
-
Alessandra Tedeschi (2)
-
Alex Carney (1)
-
Alex Carolan (3)
-
Alex Francisco Herrera (1)
-
Alex Herrera (1)
-
Alex Sieg (1)
-
ALEX trial (1)
-
Alexander Andreev-Drakhlin (1)
-
Alexander Eggermont (1)
-
Alexander N. Shoushtari (1)
-
Alexander Pine (1)
-
Alexander R. Ende (1)
-
Alexander van Akkooi (1)
-
Alexandra Maertens (1)
-
Alexandra Vitale (1)
-
Alexis Browning (1)
-
ALFA/Clara (1)
-
Alfred Lee (1)
-
Alfred Neugut (1)
-
algorithm (1)
-
Ali Raza Khaki (1)
-
Alice Chung (2)
-
Alice Goodman (1485)
-
Alice Goodman and Caroline Helwick (3)
-
Alice Mims (1)
-
Alice Shaw (5)
-
Alice Tsang Shaw (2)
-
Aline Charabaty (1)
-
Aline Fusco Fares (1)
-
Alison Jefferies (1)
-
Alison Loren (2)
-
ALK (4)
-
ALK fusion (1)
-
ALK inhibitors (1)
-
ALK positive (2)
-
ALK testing (1)
-
ALL (12)
-
Allan Espinosa (1)
-
Allegheny General Hospital (1)
-
Allen Lichter (9)
-
alliance (1)
-
ALLIANCE A031201 trial (1)
-
ALLIANCE A031203 trial (1)
-
Alliance trial (2)
-
Allison Applebaum (9)
-
Allison Harvey (1)
-
Allison Kurian (1)
-
Allison Magnuson (1)
-
Allison Rosen (1)
-
allogeneic hematopoietic cell tr (4)
-
allogeneic stem cell transplanta (2)
-
Alok Khorana (2)
-
alopecia (2)
-
alpelisib (1)
-
ALSYMPCA trial (1)
-
ALTERNATE trial (1)
-
Aly-Khan Lalani (1)
-
Alysa Fairchild (2)
-
Aman Buzdar (1)
-
Amanda Blair (1)
-
Amanda J. Redig (1)
-
Amanda McIntyre (1)
-
Amanda Narod (3)
-
ambulatory (1)
-
Amelie Harle (2)
-
Amer Zeidan (1)
-
American cancer disparities (1)
-
American Cancer Society (7)
-
American Indian (1)
-
American Indians (1)
-
American Medical Association (1)
-
American Society for Radiation O (1)
-
american society of hematology (31)
-
american society of hematoly (1)
-
American University of Beirut (1)
-
Ami Chitalia (1)
-
Amina Ahmed (1)
-
Aminah Jatoi (1)
-
Amir Steinberg (1)
-
Amit Kulkarni (1)
-
Amit Mahipal (1)
-
Amitabh Gulati (1)
-
AML (18)
-
Amy Cyr (2)
-
Amy Kiamos (1)
-
Amy MacKenzie (3)
-
Amye Tevaarwerk (1)
-
Ana I. Tergas (1)
-
Ana Maria López (1)
-
Anahid Hamparsumian (1)
-
anal squamous cell cancer (1)
-
anamorelin (3)
-
anaplastic (1)
-
anaplastic glioma (1)
-
anaplastic oligodendroglioma (1)
-
Anas Younes (3)
-
anastrozole (11)
-
and L. Jeffrey Medeiros (1)
-
andecaliximab (1)
-
Anders Widmark (1)
-
Andrea Ferrari (1)
-
Andrea Lim (1)
-
Andrea Patenaude (1)
-
Andrea Watson (2)
-
Andreas Engert (3)
-
Andreas Hochhaus (1)
-
Andreas Rimner (1)
-
Andrew Armstrong (6)
-
Andrew Chapman (1)
-
Andrew Chi (1)
-
Andrew Clamp (1)
-
Andrew Davies (2)
-
Andrew Dunbar (1)
-
Andrew Evens (2)
-
ANDREW HAHN (1)
-
ANDREW HERTLER (1)
-
Andrew James Martin (3)
-
Andrew Ko (2)
-
Andrew Martin (1)
-
Andrew Roth (2)
-
Andrew S. Epstein (1)
-
Andrew Seidman (24)
-
Andrew Zelenetz (10)
-
Andriy Hrynkiv (1)
-
androgen deprivation (3)
-
androgen deprivation therapy (6)
-
androgen receptor (1)
-
androgen receptor-positive (1)
-
androgen suppression (1)
-
androgen-deprivation therapy (7)
-
androgens (1)
-
Andy Lindsay (1)
-
Anees Chagpar (2)
-
anemia (2)
-
anesthetics (1)
-
Angela Bradbury (1)
-
Angela Pang (1)
-
angiosarcoma (1)
-
Anil D'Cruz (2)
-
Anil Sood (1)
-
Animesh Pardanani (1)
-
Anis Hamid (1)
-
Anita D'Souza (2)
-
Anita Mahajan (2)
-
Anita O'Donovan (1)
-
Anjali Advani (1)
-
Ann Farrell (1)
-
Ann Graham (1)
-
ann h. partridge (1)
-
Ann Klopp (1)
-
Ann Partridge (8)
-
Ann Ramer (1)
-
Anna Patrikidou (1)
-
Anna Rachelle Mislang (1)
-
Anne Blaes (2)
-
Anne Chiang (1)
-
Anne Covey (1)
-
Anne Jacobs (1)
-
Anne Katz (1)
-
Anne Kimha (1)
-
Annick Desjardins (1)
-
Annie Howell (1)
-
Ann-Lii Cheng (1)
-
announce trial (1)
-
anorexia (3)
-
Anschutz Cancer Pavilion (1)
-
Anthony Back (3)
-
ANTHONY D’AMICO (1)
-
Anthony D'Amico (3)
-
Anthony Olszanski (11)
-
Anthony Perre (1)
-
Anthony Zietman (6)
-
anthracycline (3)
-
anthracycline-based chemotherapy (1)
-
antiandrogen therapy (2)
-
anti-androgen therapy (1)
-
antiangiogenic (1)
-
antiangiogenic agent (1)
-
anti-B-cell maturation antigen (1)
-
antibiotics (1)
-
antibody blockade (1)
-
antibody drug conjugate (1)
-
antibody IMAB362 (2)
-
antibody-drug conjugate (2)
-
anti-CD19 (2)
-
anti-CD19 monoclonal antibody (1)
-
anti-CD22 (1)
-
anticoagulation (1)
-
anticonvulsant (1)
-
anti–CTLA-4 (1)
-
antidepressant agents (1)
-
antiestrogen therapy (1)
-
anti-GD2 (2)
-
anti-PD-1 (1)
-
anti–PD-1 (3)
-
anti–PD-L1 (1)
-
anti-PD-L1 antibody (1)
-
anti-PLD1 monoclonal antibody (1)
-
antipsychotic (1)
-
antitumor effect (1)
-
antitumor immunity (1)
-
anti-VEGF (1)
-
Anton Barchuk (1)
-
Antonio C. Wolff (1)
-
Antonio Castaneda (2)
-
Antonio Palumbo (2)
-
anxiety (6)
-
ANZUP (3)
-
apact (1)
-
apalutamide (2)
-
Apar Kishor Ganti (4)
-
apatorsen (1)
-
APHINITY trial (1)
-
APL (1)
-
app (2)
-
aprepitant (3)
-
Aram Demirjian (1)
-
aramis trial (2)
-
Arash Asher (1)
-
ARCHER 1050 (1)
-
ARCHER 1050 trial (1)
-
Areej El-Jawahri (3)
-
ARIEL3 (1)
-
Arielle Elkrief (2)
-
Arizona Breast Cancer Specialist (1)
-
Arjun Balar (1)
-
Arjun Patel (1)
-
Arjun Vasant Balar (1)
-
arm mobility (1)
-
Armando Armas (1)
-
Armando E. Giuliano (2)
-
Armando Giuliano (1)
-
Armando Sardi (1)
-
Armitage (1)
-
Arnaud Scherpereel (2)
-
aromatase inhibitor (12)
-
aromatase inhibitors (4)
-
arrow trial (1)
-
arsenic (1)
-
Artemis Health Institute (1)
-
Artemis Hospitals (1)
-
arterial-directed therapy (1)
-
arthralgia (1)
-
Arti Hurria (3)
-
artificial intelligence (1)
-
Asan Medical Center (1)
-
ASCEND-5 trial (1)
-
ascend-7 (1)
-
ASCENDE-RT (1)
-
ASCO (1358)
-
ASCO 2015 (53)
-
ASCO 2016 (63)
-
ASCO 2017 (55)
-
ASCO 2018 (67)
-
asco 2019 (69)
-
asco 2019, breast cancer, capecitabine, her2-positive, lapatinib, metastatic, nala trial, neratinib (1)
-
ASCO Choosing Wisely (1)
-
ASCO Communications (3)
-
ASCO Connection (1)
-
ASCO Palliative Care (12)
-
asco post (51)
-
ASCO President (2)
-
ASCO Publishing (1)
-
ASCO Quality Care (11)
-
ASCO Quality Care 2017 (13)
-
asco quality training program (1)
-
asco sitc (19)
-
ASCO Virtual Scientific Program (1)
-
ASCO20 (49)
-
ASCO-ECCO (1)
-
ascoo 2019 (1)
-
ASCO-SITC 2017 (11)
-
ASCT (3)
-
ASH (5)
-
ASH 2015 (33)
-
ASH 2016 (25)
-
ASH 2017 (11)
-
ASH 2018 (18)
-
ash 2020 (1)
-
ash annual meeting (48)
-
Asher Chanan-Khan (3)
-
Ashfaq Marghoob (1)
-
Ashley Cimino-Mathews (1)
-
Ashley Wysong (1)
-
Asian (1)
-
aspire trial (1)
-
aspirin (2)
-
assays (1)
-
Assistance Publique Hopitaux De (1)
-
assisted suicide (1)
-
Association of Community Cancer (1)
-
ASTRO (2)
-
ASTRO 2015 (19)
-
ASTRO 2017 (12)
-
ASTRO 2018 (11)
-
astro 2020 (9)
-
astro annual meeting (14)
-
atempt trial (1)
-
atezolizumab (24)
-
Athalia Rachel Pyzer (1)
-
Atiqur Rahman (1)
-
atra (1)
-
AUA (1)
-
AUGMENT trial (1)
-
AUGUSTO LEÓN (1)
-
Aurelius Omlin (1)
-
autoimmune disease (2)
-
autologous hematopoietic cell tr (1)
-
autologous stem cell transplant (6)
-
autologous transplantation (1)
-
autonomic imbalance (1)
-
avasopasem manganese (1)
-
avelumab (5)
-
Avni Desai (1)
-
Avraham Eisbruch (1)
-
Avrum Bluming (2)
-
Axel Grothey (9)
-
axicabtagene ciloleucel (2)
-
axillary lymph node dissection (1)
-
axitinib (6)
-
AYA cancer (2)
-
AYA oncology (3)
-
AYA survivors (1)
-
ayalew tefferi (6)
-
Ayesha Munir (1)
-
azacitidine (6)
-
AZD5363 (1)
-
Azienda Ospedaliera Niguarda Cà (1)
-
B.J. Rimel (1)
-
B-40 trial (1)
-
B-51 trial (1)
-
Babara Gitlitz (1)
-
baf-type (1)
-
Bahar Javdan (1)
-
Bain Capital Life Sciences (1)
-
BALKEES ABDERRAHMAN (1)
-
b-all (1)
-
Barb Young (1)
-
Barbara Boughton (3)
-
Barbara Gitlitz (1)
-
Barbara K. Rimer (1)
-
Barbara McAneny (2)
-
Barnardo Rapoport (1)
-
Barnett Kramer (2)
-
Barrie Cassileth (21)
-
Barrie R. Cassileth (1)
-
barriers to care (1)
-
barriers to quality (1)
-
Barry Paul (1)
-
Barts Cancer Institute (2)
-
Barts Health NHS Trust (2)
-
basal cell carcinoma (2)
-
basal type breast cancer (1)
-
basic science (1)
-
basket trial (1)
-
basket trials (1)
-
Bates Moses (1)
-
Baylor College of Medicine (5)
-
BC2001 trial (1)
-
B-cell ALL (3)
-
B-cell lymphoma (2)
-
B-cell malignancies (1)
-
B-cell non-Hodgkin lymphoma (1)
-
B-cell precursor (1)
-
BCG (1)
-
BCIRG-006 study (1)
-
bcl-2 (1)
-
bcl2 inhibitor (1)
-
BCMA (1)
-
BEACON CRC (2)
-
Beat Thürlimann (1)
-
Beatriz Korc-Grodzicki (1)
-
BELIEF trial (1)
-
BELLE-3 trial (1)
-
Bellinda King-Kallimanis (1)
-
bendamustine (9)
-
bendustamine (1)
-
Benjamin Anderson (1)
-
Benjamin Besse (2)
-
Benjamin Movsas (1)
-
Benjamin Smith (4)
-
Benyam Muluneh (1)
-
benzodiazepines (1)
-
Bernard Escudier (7)
-
Bernard Fisher (2)
-
Bernardo Rapoport (1)
-
Bertrand Coiffier (6)
-
Bertrand Routy (1)
-
best care (1)
-
Best of ASCO (1)
-
beta-thalassemia (1)
-
Beth Faiman (1)
-
Beth Fairchild (1)
-
Beth Howard (3)
-
Beth Israel Deaconess (1)
-
Beth McLellan (1)
-
BETTY DICKER (1)
-
Betty Ferrell (2)
-
Betty Hamilton (1)
-
bevacizumab (29)
-
Beverly Canin (1)
-
Beverly Vuckovich (1)
-
BGB-290 (1)
-
BGB-A317 (1)
-
BGJ398 (1)
-
Bhavana Konda (1)
-
Bhishamjit Chera (1)
-
Bhuvanesh Singh (1)
-
bicalutamide (4)
-
big data (3)
-
bilateral (1)
-
bilateral mastectomy (1)
-
BILCAP trial (1)
-
bile duct cancer (1)
-
biliary cancer (1)
-
biliary tract cancer (6)
-
Bill Brummel (1)
-
Bill Gradishar (1)
-
Bill McClain (1)
-
Bin McLaurin (1)
-
binimetinib (2)
-
biochemical control (1)
-
biochemical failure (1)
-
biochemical recurrence (1)
-
biochemical relapse (1)
-
biologics (1)
-
biology in younger patients (1)
-
biology of pain (1)
-
biomarker (13)
-
biomarker stratification (2)
-
biomarkers (10)
-
biopsy (2)
-
biosimilar (1)
-
biosimilars (4)
-
Biosimilars (1)
-
biphosphonate treatment (1)
-
BIRCH trial (1)
-
biscay trial (1)
-
Bishal Gyawali (1)
-
Bishoy Faltas (5)
-
bisphophonates (1)
-
BITE (1)
-
black patients (2)
-
bladder cancer (40)
-
Bladder Cancer (20)
-
bladder preservation (1)
-
Blase N. Polite (1)
-
Blase Polite (1)
-
blast phase (1)
-
bleomycin (1)
-
blinatumomab (4)
-
blinatumumab (1)
-
blood biomarker (1)
-
blood cancer (1)
-
blood-brain barrier (2)
-
blu-667 (1)
-
Bob Carlson (2)
-
Bob Levis (1)
-
Bobby Daly (1)
-
body composition (2)
-
body image (1)
-
BOLERO-2 (1)
-
BOLERO-4 (1)
-
bone fractures (1)
-
bone marrow transplant (1)
-
bone metastases (3)
-
Bonnie Addario (1)
-
Bonnie Glisson (1)
-
Bonnie Rochman (1)
-
Bordeaux University Hospital (2)
-
borderline disease (1)
-
borderline resectable (1)
-
borderline resectable pancreatic (1)
-
Borealis-2 (1)
-
Boris Sepesi (1)
-
bortezomib (7)
-
bowel function (1)
-
brachytherapy (3)
-
brachytherapy implant (1)
-
Brad Kahl (3)
-
Bradley Monk (2)
-
Bradley Reames (1)
-
Bradley Zebrack (2)
-
BRAF (2)
-
BRAF mutation (2)
-
BRAF mutations (1)
-
BRAF V600 (2)
-
braf v600e (2)
-
BRAF-mutated tumors (1)
-
brain cancer (5)
-
brain metastases (11)
-
Branden May (1)
-
Brandon May (21)
-
Brandon Smaglo (1)
-
BRCA (8)
-
BRCA mutations (1)
-
BRCA status (1)
-
BRCA1 (4)
-
brca1/2 (1)
-
BRCA2 (4)
-
BRCA-mutated (1)
-
breast (1)
-
breast cancer (209)
-
Breast Cancer (53)
-
breast cancer diversity (1)
-
breast cancer genomics (1)
-
breast cancer in young women (2)
-
breast cancer incidence (1)
-
breast cancer mortality (1)
-
breast cancer prevention (1)
-
breast cancer screening (1)
-
breast cancer survivor (3)
-
breast cancer survivors (3)
-
breast conservation (1)
-
breast conserving surgery (2)
-
breast irradiation (1)
-
breast preserving surgery (1)
-
breast resection (1)
-
breast tumors (1)
-
breast-conserving surgery (1)
-
breast-conserving therapy (1)
-
Brenda Sandmaier (1)
-
Brendan F. Curley (1)
-
Brendan Guercio (2)
-
brentuximab vedotin (5)
-
bretrand coiffier (1)
-
Brett Wilson (1)
-
Bria Meyer (2)
-
Brian Bolwell (1)
-
Brian Chapin (1)
-
Brian Chen (1)
-
Brian Kavanagh (2)
-
Brian Rini (5)
-
Brian Weiss (1)
-
Brian Wolpin (1)
-
Bridgett Harr (2)
-
brigatinib (1)
-
Brigham and Women’s (1)
-
Brigham and Women’s Hospital (1)
-
Brigham and Women's Cancer Center (1)
-
Brigham and Women's Hospital (1)
-
BRIM8 trial (1)
-
Brinker Award lecture (1)
-
British Columbia Cancer Agency (4)
-
Britta Weigelt (1)
-
Brittany Bychkovsky (1)
-
brocade 3 (1)
-
bronchoscopy (1)
-
Bruce A. Chabner (1)
-
Bruce Cheson (6)
-
Bruce E. Johnson (1)
-
Bruce Haffty (1)
-
Bruce Johnson (3)
-
Bruce Levine (2)
-
Bruce Minsky (5)
-
Bruno Medeiros (1)
-
Brustzentrum der Universität Mün (1)
-
bruton's tyrosine kinase (1)
-
BTK (2)
-
BTK inhibitors (2)
-
buparlisib (1)
-
burden (1)
-
burden of care (1)
-
burden of treatment (1)
-
Burkitt lymphoma (2)
-
Burkitt’s lymphoma (1)
-
bursectomy (1)
-
business (5)
-
C.B. Allard (1)
-
cabazitaxel (4)
-
CABOSUN (1)
-
CABOSUN trial (1)
-
cabozantinib (9)
-
cachexia (5)
-
cachexia quality of life (1)
-
CAF (1)
-
calcium (1)
-
Caleb Dulaney (1)
-
CALGB 40502 (1)
-
CALGB 40503 (1)
-
CALGB 40601 (1)
-
CALGB 40601 Alliance (1)
-
calgb 40603 (1)
-
CALGB 40903 (1)
-
CALGB 80802 (1)
-
CALGB 80803 (1)
-
CALGB 89803 (2)
-
CALGB alliance trial (2)
-
CALGB trial (1)
-
CALGB/Alliance 50303 (1)
-
CALGB/Alliance 50604 (1)
-
CALM psychological intervention (1)
-
Calvin Dykstra (1)
-
Cameron Turtle (2)
-
cancer (60)
-
Cancer and Aging Research Group (1)
-
cancer biomarker (1)
-
cancer care (3)
-
cancer caregiving (1)
-
cancer centers (2)
-
Cancer Council Queensland (1)
-
cancer delirium (1)
-
cancer diagnosis (1)
-
cancer discoveries (1)
-
cancer drug development (1)
-
cancer experience (1)
-
cancer genetics (1)
-
Cancer Genome Atlas (1)
-
cancer imaging (1)
-
cancer in India (1)
-
cancer in South America (1)
-
cancer in the Middle East (1)
-
cancer incidence (2)
-
cancer management (2)
-
cancer metastases (1)
-
cancer mortality (3)
-
cancer of the unknown primary (1)
-
cancer outcomes (3)
-
cancer pain (8)
-
cancer pain management (1)
-
cancer prevention (2)
-
cancer recurrence (4)
-
cancer research (4)
-
Cancer Research UK (1)
-
Cancer Research UK Centre (1)
-
cancer risk (1)
-
cancer screening (6)
-
cancer staging (4)
-
cancer support services (1)
-
cancer surgery (1)
-
cancer survival (1)
-
cancer survivor (16)
-
cancer survivors (1)
-
cancer survivorship (4)
-
Cancer Survivorship Symposium (23)
-
cancer treatment (6)
-
Cancer Treatment Centers of Amer (2)
-
cancer treatment outcomes (1)
-
cancer vaccine (2)
-
cancer vaccines (1)
-
CancerCare (1)
-
CancerLinQ (4)
-
cancer-related pain (1)
-
cancer-specific survival (1)
-
candor trial (1)
-
capecitabine (15)
-
caplacizumab (1)
-
CAPTIVATE trial (1)
-
car t (1)
-
CAR T cell (1)
-
CAR T cell therapy (2)
-
CAR T cells (2)
-
CAR T-cell (3)
-
car t-cell therapy (6)
-
CAR T-cells (2)
-
CAR therapy (1)
-
Cara Glynn (1)
-
Carbone Cancer Center (2)
-
carboplatin (12)
-
carcinomatosis (1)
-
CARD trial (1)
-
cardiac effects (1)
-
cardiac radiation (1)
-
cardiac toxicity (1)
-
Cardiff University (1)
-
Cardinale Smith (1)
-
cardiotoxicity (2)
-
cardiovascular (1)
-
cardiovascular disease (3)
-
cardiovascular toxicities (1)
-
care coordination (1)
-
care disparities (1)
-
care plan (2)
-
care program (1)
-
caregiver (2)
-
caregivers (2)
-
Carey Anders (2)
-
carfilzomib (5)
-
Carina Storrs (1)
-
Carl Singerman (1)
-
CARLA CASULO (1)
-
Carlo Alfredo Clerici (1)
-
Carlos Arteaga (2)
-
Carlos Barrios (1)
-
Carlos Rene Valdez (1)
-
Carmea trial (2)
-
carmena (1)
-
Carol Goodrich (1)
-
Carol Kuehnert (1)
-
Carol Lee (1)
-
Carol Tietz (1)
-
Carol Veio (1)
-
CAROLINA TANNENBAUM-BARUCHI (1)
-
Carolina Urologic Research Center (1)
-
Carolinas Medical Center (1)
-
Caroline Helwick (2061)
-
Caroline Helwick and Alice Goodman (3)
-
Caroline Hopkins (3)
-
Caroline McNeil (69)
-
Caroline Robert (2)
-
Caroline Wellbery (1)
-
Carolyn Hendricks (1)
-
Carolyn Matthews (1)
-
Carolyn Presley (2)
-
Carolyn Runowicz (1)
-
Carrie Kreiswirth (1)
-
Carrie Snyder (1)
-
Carson Rolleri (4)
-
CAR-T (2)
-
CAR-T cells (1)
-
cas9 (1)
-
CASSINI (1)
-
castelman disease (1)
-
castleman disease collaborative network (1)
-
CASTOR trial (4)
-
castrate-resistant (2)
-
castration resistant (1)
-
castration-resistant (14)
-
castration-resistant prostate ca (2)
-
castration-sensitive (3)
-
Catherine C. Coombs (1)
-
Catherine Coombs and Anthony Mato (1)
-
Catherine Park (2)
-
Catherine Thieblemont (2)
-
Cathy Eng (2)
-
CATNON trial (1)
-
Catriona McNeil (3)
-
catumaxomab (1)
-
Caucasian (1)
-
cause-specific mortality (1)
-
CBT (1)
-
cc-486 (1)
-
CCF (2)
-
CCGA (1)
-
CCOG 1102 (1)
-
CCTG/AGITG napabucasin (1)
-
CD19 (1)
-
CD-19 (1)
-
CD19+ lymphoma (1)
-
CD-20 positive (1)
-
CD274 (1)
-
CD30 (2)
-
CD-30 (1)
-
CD38 (1)
-
cd79a (1)
-
CD81 cells (1)
-
CDK inhibitor (1)
-
CDK4 inhibitor (1)
-
CDK4/6 inhibitor (1)
-
CDK4/6 Inhibitors (1)
-
CDK46 (1)
-
CEA tumor marker (1)
-
Cedars-Sinai (6)
-
Cedars-Sinai Medical Center (3)
-
cediranib (1)
-
Ceilidh Eaton Russell (1)
-
celecoxib (1)
-
Celestia Higano (2)
-
CELESTIAL (2)
-
cell-free DNA (1)
-
cellular therapy (2)
-
cemiplimab (2)
-
Center for International Blood a (1)
-
central nervous system metastase (1)
-
Centre Antoine-Lacassagne (2)
-
Centre Eugene Marquis (2)
-
Centre Leon Berard (1)
-
Centre Léon Bérard (1)
-
Centre R Gauducheau (1)
-
Centre Régional de Lutte Contre (1)
-
CEO (1)
-
Cerdulatinib (1)
-
ceritinib (4)
-
cervical cancer (8)
-
Cesar A. Santa-Maria (2)
-
Cesar Santa-Maria (1)
-
cetuximab (10)
-
ch14.18/CHO (2)
-
CHAARTED trial (1)
-
Chadi Nabhan (1)
-
challenges in cancer care (1)
-
Chanan-Khan (1)
-
Chandrakanth Are (43)
-
Channing Paller (5)
-
Charity Oyedeji (1)
-
Charles Bennett (4)
-
Charles Blanke (1)
-
Charles Drake (1)
-
Charles Duvall (2)
-
charles e. geyer (2)
-
Charles E. Geyer Jr. (3)
-
Charles F. von Gunten (2)
-
Charles L. Bennett (5)
-
Charles Loprinzi (2)
-
Charles Rudin (1)
-
CHARLES RYAN (1)
-
Charles Schiffer (2)
-
Charles Simone (1)
-
Charles von Gunten (3)
-
charlo (1)
-
Charlotte Bath (701)
-
CHARU AGGARWAL (2)
-
Chase Doyle (510)
-
chasing my cure (1)
-
Chau Dang (2)
-
Checkmate (2)
-
CheckMate 025 (1)
-
CheckMate 032 (3)
-
CheckMate 039 (1)
-
CheckMate 067 (1)
-
CheckMate 141 (1)
-
CheckMate 142 (1)
-
CheckMate 214 (2)
-
CheckMate 214 trial (1)
-
checkmate 227 (1)
-
checkmate 238 (1)
-
CheckMate 238 trial (1)
-
CheckMate 275 (1)
-
checkmate 384 (1)
-
checkmate 650 (1)
-
CheckMate 67 (2)
-
CheckMate-032 (1)
-
CheckMate-142 (2)
-
checkpoint antibodies (2)
-
checkpoint blockade (3)
-
checkpoint inhibitor (4)
-
checkpoint inhibitors (5)
-
checkpoint kinase inhibitor (1)
-
chemobrain (1)
-
chemoendocrine (2)
-
chemoimmunotherapy (4)
-
chemoimmunotherapy, first-line therapy, follicular lymphoma, nccn hematologic malignancies, targeted biologics (1)
-
chemopreventative (2)
-
chemoradiation (6)
-
chemoradiotherapy (9)
-
chemoresistance (1)
-
chemotherapy (80)
-
chemotherapy duration (1)
-
chemotherapy errors (1)
-
chemotherapy naive (1)
-
chemotherapy toxicity (1)
-
chemotherapy-induced (1)
-
chemotherapy-induced peripheral (1)
-
chemotherapy-ineligible (1)
-
chemotherapy-naive (3)
-
chemotherapy-naïve (1)
-
Cheryl Ewing (1)
-
Cheryl Krafft (1)
-
chest infections (1)
-
chest wall radiation (1)
-
Chevalier Jackson (1)
-
CHHiP trial (2)
-
Chiara Magni (1)
-
Chijioke Nze (1)
-
childhood ALL (2)
-
childhood cancer (2)
-
childhood cancer survivor (2)
-
Childhood Cancer Survivor Study (1)
-
childhood cancer survivors (2)
-
children (1)
-
Children’s Oncology Group (1)
-
chimeric antigen receptor (5)
-
China (1)
-
Chinese U of Hong Kong (1)
-
Chinese University (1)
-
Chinese University of Hong Kong (5)
-
Chip Baldwin (1)
-
Chloe Atreya (2)
-
chlorambucil (2)
-
cholangiocarcinoma (2)
-
Choosing Wisely Campaign (1)
-
CHOP (2)
-
CHOP-R (1)
-
CHP (1)
-
CHRIS LABAKI (1)
-
Chris Leonardis (1)
-
Chris O'Brien Lifehouse (1)
-
Chris Parker (1)
-
Christian Blank (2)
-
Christian Carrie (2)
-
Christian Nelson (1)
-
Christian-Albrechts University K (2)
-
Christiane Querfeld (1)
-
Christiane Voit (1)
-
Christie NHS Foundation Trust (3)
-
Christina Best (1)
-
Christina Chu (2)
-
Christina S. Chu (1)
-
Christina Seluzicki (1)
-
Christine Berg (1)
-
Christine Boers-Doets (1)
-
Christoph Zielinski (2)
-
Christopher Allard (1)
-
Christopher Barker (1)
-
Christopher Buettner (1)
-
Christopher Campen (5)
-
Christopher Flowers (1)
-
CHRISTOPHER HOIMES (1)
-
Christopher Kelsey (1)
-
Christopher Logothetis (1)
-
Christopher Recklitis (4)
-
Christopher Rose (2)
-
Christopher Steer (1)
-
Christopher Sweeney (9)
-
Christopher Willett (1)
-
chronic disease (1)
-
chronic lymphocytic leukemia (21)
-
chronic morbidity (1)
-
chronic myeloid leukemia (8)
-
chronic myelomonocytic leukemia (1)
-
chronic pain (1)
-
chronic-phase CML (2)
-
Chung-Han Lee (1)
-
Ciara Freeman (1)
-
CIBMTR (1)
-
CIBOMA/GEICAM Trial (1)
-
Cicely Saunders (1)
-
Cincinnati Children's Hospital M (1)
-
Cindy Brown (1)
-
Cindy Chavez (1)
-
CINV (3)
-
CINV prevention (1)
-
CIPN (1)
-
circulating free DNA (2)
-
circulating tumor cells (6)
-
circulating tumor DNA (10)
-
cisplarin (1)
-
cisplatin (19)
-
cisplatin-based chemotherapy (2)
-
cisplatin-ineligible (2)
-
Città della Salute e della Scie (1)
-
City of Hope (19)
-
Clara Bloomfield (1)
-
claridhy trial (1)
-
classical Hodgkin lymphoma (1)
-
Claus Garbe (4)
-
Clayton B. Hess (1)
-
CLDN18.2 positive disease (2)
-
clear cell (2)
-
clear cell rcc (1)
-
clear cell renal cancer (1)
-
CLEOPATRA trial (1)
-
Cleveland Clinic (19)
-
Cliff Goodman (1)
-
Cliff Hudis (5)
-
clifford a. hudis (2)
-
Clifford Goodman (1)
-
Clifford Hudis (31)
-
clinical (1)
-
clinical benefit (1)
-
clinical cancer advances (1)
-
clinical decision-making (2)
-
clinical endpoint (1)
-
clinical management (1)
-
clinical outcomes (2)
-
clinical pathways (2)
-
clinical practice (1)
-
clinical research (1)
-
clinical resources (1)
-
clinical treatment score (1)
-
clinical trial (1)
-
clinical trial eligibility (2)
-
clinical trial screening (1)
-
clinical trials (12)
-
clinician-patient communication (1)
-
CLL (29)
-
clofarabine (1)
-
CME (1)
-
CML (10)
-
CMML (2)
-
CMS (2)
-
CNS cancer (1)
-
CNS cancers (1)
-
CNS Cancers (1)
-
CNS disease (1)
-
CNS involvement (1)
-
CNS metastases (1)
-
CNS prophylaxis (2)
-
CNS-penetrable (1)
-
cobimetinib (1)
-
cognition (1)
-
cognitive behavior therapy (1)
-
cognitive decline (1)
-
cognitive failure (1)
-
cognitive function (3)
-
Coiffier (1)
-
co-insurance (1)
-
Cold Spring Harbor Laboratory (1)
-
Colette Owens (1)
-
Colin Weekes (1)
-
colitis (2)
-
collaborative pain management (1)
-
collection kit (1)
-
COLLEEN M. FELTMATE (1)
-
Colleen Smith (1)
-
COLO-001 trial (1)
-
colon cancer (11)
-
colony-stimulating factors (1)
-
colopec trial (1)
-
colorectal (1)
-
colorectal cancer (36)
-
Colorectal Cancer (24)
-
colorectal cancer liver metastases (1)
-
colorectal cancer survivor (1)
-
Columbia University (2)
-
Columbia University Medical Cent (2)
-
Columbia University Medical Center (1)
-
COLUMBUS trial (1)
-
COMBI-AD (1)
-
combination immunotherapy (4)
-
combination therapies (3)
-
combination therapy (3)
-
combination treatments (1)
-
combined positive score (1)
-
Coming Soon (1)
-
Commission on Cancer (1)
-
communication barrier (1)
-
communication in oncology (2)
-
communication studies (1)
-
community (1)
-
community cancer center (1)
-
community oncology (7)
-
community practice (2)
-
community practices (1)
-
community setting (2)
-
community sites (1)
-
comorbidites (1)
-
comorbidities (3)
-
comorbidity score (1)
-
comorbitides (1)
-
compass trial (2)
-
completely resected (1)
-
complication rate (1)
-
comprehensive cancer centers (1)
-
computed tomography (1)
-
computer assistance (1)
-
computerized evaluation (1)
-
concurrent radiation (1)
-
Cone Health Cancer Center (1)
-
conformal radiation (1)
-
Conquer Cancer Foundation (2)
-
Conquer Fear (1)
-
consolidation chemotherapy (1)
-
consolidation radiotherapy (1)
-
consolidative radiotherapy (1)
-
consolidative therapy (1)
-
continued care (1)
-
continuing medical education (1)
-
contralateral breast cancer (1)
-
conventional (1)
-
conventional fractionation radio (1)
-
conventionally fractionated (2)
-
conventionally fractionated radi (1)
-
conversation guides (1)
-
co-occurring mutations (1)
-
cooling cap (1)
-
COPD (1)
-
Copenhagen University Hospital (4)
-
coping mechanisms (1)
-
Cora N. Sternberg (1)
-
Cora Sternberg (6)
-
CORAL trial (1)
-
core biopsy (1)
-
Corey Cutler (1)
-
Cornelis van de Velde (1)
-
coronary calcification (1)
-
coronary heart disease (1)
-
coronavirus (34)
-
coronavirus italy (4)
-
coronavirus waves (1)
-
correlative studies (1)
-
cosmesis (1)
-
cosmetic outcome (1)
-
cost (1)
-
cost analysis (2)
-
cost benefit (1)
-
cost curve (1)
-
cost of care (21)
-
Cost of Care (2)
-
cost reductions (1)
-
cost savings (1)
-
cost-effectiveness (3)
-
cough (2)
-
cough mechanisms (1)
-
counseling (1)
-
course of therapy (1)
-
course of treatment (1)
-
Courtney Davis (1)
-
COVID-19 (22)
-
COVID-19 (21)
-
covid-19 research (1)
-
COX-2 over expression (1)
-
cps (1)
-
CPX-351 (1)
-
CR30 (1)
-
Craig Alguire (1)
-
Craig Earle (1)
-
Craig Moskowitz (3)
-
Craig Pollack (2)
-
cranial radiotherapy (1)
-
CREATE-X clinical trial (1)
-
Creighton University (1)
-
CRISPR (1)
-
Cristina Meazza (1)
-
criteria expansion (1)
-
CRITICS trial (1)
-
crizotinib (9)
-
Cross Cancer Institute (1)
-
crpc (3)
-
Crystal Denlinger (2)
-
CSF (1)
-
CT follow-up (1)
-
CT scan (5)
-
CT screening (1)
-
CT019 (1)
-
cT3 rectal cancer (1)
-
cT4 rectal cancer (1)
-
CTCL (1)
-
CTCs (5)
-
ctDNA (7)
-
ctla-4 (1)
-
ctnda (1)
-
cts5 (1)
-
cultural barriers (1)
-
cultural differences (1)
-
CUMC (2)
-
curable cancer (1)
-
curative surgery (1)
-
cutaneous melanoma (1)
-
cutaneous SCC (1)
-
cutaneous squamous cell carcinom (2)
-
cutaneous T cell lymphoma (1)
-
cutoff (1)
-
cutting-edge treatment (2)
-
CXCR4 inhibitor (1)
-
cyclophosphamide (7)
-
cyclosporine (1)
-
Cynthia Hayes (1)
-
Cynthia Sears (1)
-
cystectomy (2)
-
cytarabine (2)
-
cytopenias (1)
-
D. Ross Camidge (1)
-
D538G mutation (1)
-
dabrafenib (6)
-
dabrafenib monotherapy (1)
-
dacarbazine (2)
-
dacomitinib (2)
-
DA-EPOCH-R (2)
-
DA-EPOCH-R trial (1)
-
Dale Maloney (1)
-
dalteparin (1)
-
Damien Hansra (3)
-
Dan Labriola (1)
-
Dan Longo (2)
-
Dan Shapiro (1)
-
Dan Zandberg (1)
-
Dana Barnea (2)
-
Dana Farber (3)
-
Dana Farber Cancer Insitute (3)
-
Dana Farber Cancer Institute (1)
-
Dana Stewart (1)
-
Dana-Farber (27)
-
Dana-Farber Cancer Institute (61)
-
Dana-Farber Clinical Pathways (1)
-
Dana-Farber Institute (1)
-
Danelle James (1)
-
Daniel A. Goldstein (1)
-
DANIEL ANAYA (1)
-
Daniel Barocas (1)
-
Daniel Cahill (2)
-
Daniel Chang (1)
-
Daniel DeAngelo (1)
-
Daniel den Hoed Cancer Center (1)
-
Daniel Epner (4)
-
Daniel F. Hayes (6)
-
Daniel Garza (1)
-
Daniel Geynisman (1)
-
Daniel Goldstein (1)
-
Daniel Gomez (1)
-
Daniel Haller (3)
-
Daniel Hamstra (1)
-
Daniel Hayes (4)
-
Daniel Heng (1)
-
Daniel J. Lenihan (1)
-
Daniel Kopans (2)
-
Daniel Lin (1)
-
Daniel Morgensztern (1)
-
Daniel Petrylak (1)
-
Daniel Rayson (4)
-
Daniel Richardson (1)
-
Daniel Spratt (1)
-
Daniel Vilarim Araujo (1)
-
Daniel Vorobiof (4)
-
Daniel W. Lin (1)
-
Danielle Ripley Burgess (1)
-
DANIELLE THOLEY (1)
-
danorubicin (1)
-
daratumumab (14)
-
Darcy Lewis (1)
-
Dario Altieri (1)
-
Dario Trapani (1)
-
darolutamide (2)
-
Darrell Skaggs (1)
-
Dartmouth-Hitchock (1)
-
dasatinib (1)
-
Dasha Shkurpela (1)
-
data set (1)
-
DATA trial (1)
-
daunorubicin (2)
-
DAVID BRAUN (1)
-
David Dearnaley (2)
-
David Ettinger (2)
-
David Fredricks (1)
-
David G. Pfister (1)
-
David Geffen School of Medicine (1)
-
David Gerber (2)
-
David Gershenson (1)
-
David Gustafson (1)
-
David Henry (5)
-
David Hyman (1)
-
David Hysong (1)
-
David Ilson (3)
-
David Irwin (1)
-
David J. Kopsky (1)
-
David Kim (1)
-
David Kissane (3)
-
David Korones (1)
-
David M. O'Malley (1)
-
David Maloney (2)
-
David McDermott (1)
-
David Mitchell (1)
-
David Nathan (1)
-
David Neises (1)
-
David O’Malley (1)
-
David Porter (3)
-
David Posner (1)
-
David Quinn (1)
-
David Ryan (1)
-
David Steensma (3)
-
David Straus (2)
-
David Tuveson (1)
-
David Victorson (1)
-
David Wellenstein (1)
-
David Williams (1)
-
David Wise (1)
-
David Ziegler (1)
-
Dawn Hershman (4)
-
Dawn Lemanne (2)
-
Dawn Yates (1)
-
DBCG778 (1)
-
DCIS (6)
-
Dean Bajorin (3)
-
Deanna King (1)
-
death (1)
-
Death With Dignity Act (1)
-
death with dignity laws (1)
-
Debbie Davis (1)
-
Debbie Wasserman Schultz (1)
-
debilitating grief (1)
-
Deborah Doroshow (1)
-
Deborah Marshall (1)
-
Debra Bowler (1)
-
Debu Tripathy (1)
-
debulking surgery (2)
-
Decipher prostate cancer classif (1)
-
decision making (1)
-
decision support (1)
-
decision-making (1)
-
decitabine (1)
-
DECOG trial (2)
-
Dee Sparacio (1)
-
deep molecular response (1)
-
deep remission (1)
-
Deepa Wadhwa (1)
-
de-escalating therapy (1)
-
Defense Health Agency (1)
-
deintensification (1)
-
deintensified therapy (1)
-
delay in care (1)
-
delirium (1)
-
delivery of care (1)
-
denintuzumab mafodotin (1)
-
Denise Lee (1)
-
Denise Leprine (1)
-
DENISE MILLSTINE (1)
-
Denise Yardley (1)
-
denosumab (3)
-
depression (9)
-
Derek Jonker (1)
-
Derek Raghavan (15)
-
dermatologic toxicities (1)
-
Derriford Hospital (1)
-
despair (1)
-
DESTINY study (1)
-
developing world (1)
-
Devorah Aschendorf (1)
-
dexamethasone (14)
-
dfs (1)
-
diagnosis (2)
-
diagnostic criteria (1)
-
diagnostics (2)
-
Diana Byrnes (1)
-
Diana Eccles (1)
-
Diana Heller (1)
-
Diana Jeffery (1)
-
Diane Portman (2)
-
Dianne Spillman (1)
-
diarrhea (2)
-
Diego Davis-Olegário (1)
-
diet (2)
-
dietary intervention (1)
-
Dieter Hoelzer (1)
-
diffuse large B cell (1)
-
diffuse large B cell lymphoma (11)
-
diffuse large B-cell lymphoma (15)
-
diffuse midline glioma (1)
-
dignicap (1)
-
Dimas Padilla (1)
-
direct oral anticoagulants (1)
-
direct-to-patient (1)
-
discontinuing therapy (1)
-
discontinuing treatment (1)
-
disease burden (1)
-
disease control (1)
-
disease heterogeneity (1)
-
disease imaging (1)
-
disease management (1)
-
disease outcomes (1)
-
disease progression (8)
-
disease recurrence (4)
-
disease staging (1)
-
disease survival (1)
-
disease-free survival (5)
-
disparities (1)
-
distant cancer recurrence (1)
-
distant disease (1)
-
distant disease–free survival (1)
-
distant lesions (1)
-
distant metastasis-free survival (1)
-
distress (7)
-
distress screening (2)
-
distress thermometer (2)
-
diversity (1)
-
DLBCL (23)
-
DLL-3 (3)
-
DNA alteration (1)
-
DNA damage (1)
-
DNA damage repair deficiencies (1)
-
DNA damage-repair pathway (1)
-
DNA mistmatch repair (1)
-
DNA repair (2)
-
DOACs (2)
-
docetaxel (31)
-
docetaxel monotherapy (1)
-
doctor-patient behavior (1)
-
Domenica Lorusso (1)
-
Don Stranathan (1)
-
Donald Abrams (1)
-
Donald Garrity (1)
-
Donald I. Abrams (1)
-
Donald L. Trump (1)
-
Dong Wook Shin (1)
-
Donna Bell (1)
-
Donna Chen (1)
-
Donna Fernandez (1)
-
Donna Piunt (1)
-
Dori Klemanski (1)
-
Dorothy Lombe (2)
-
Dorothy Turner (1)
-
dosage (2)
-
dose (1)
-
dose decrease (1)
-
dose de-escalation (1)
-
dose density (1)
-
dose escalation (3)
-
dose fractionation (1)
-
dose intensity (1)
-
dose lowering (1)
-
dose reduction (1)
-
dose response (1)
-
dose-dense chemotherapy (1)
-
double-expressor lymphoma (1)
-
double-hit lymphoma (1)
-
doublet (1)
-
Douglas Arthur (1)
-
Douglas B. Johnson (2)
-
Douglas Lowy (1)
-
Douglas Wood (3)
-
doxorubicin (8)
-
driver mutations (1)
-
droplet digital PCR (1)
-
drug approvals (1)
-
drug combination (1)
-
drug conjugates (1)
-
drug costs (1)
-
drug development (3)
-
drug disparities (1)
-
drug indications (1)
-
dry mouth (1)
-
ductal carcinoma in situ (5)
-
Duke Cancer Center (3)
-
Duke Cancer Insitute (1)
-
Duke Cancer Institute (4)
-
Duke Medical Center (1)
-
Duke University (7)
-
duloxetine (1)
-
Dung Le (6)
-
duration of treatment (1)
-
durvalumab (8)
-
duvelisib (1)
-
E. David Crawford (4)
-
E. George Elias (3)
-
E7208 trial (1)
-
early breast cancer (10)
-
early cancer detection (1)
-
early CDT (1)
-
early detection (5)
-
early distant recurrence (1)
-
early menopause (1)
-
early palliative care (3)
-
early referral (1)
-
early relapsing (1)
-
early salvage radiotherapy (1)
-
early stage (2)
-
early stage breast cancer (2)
-
early stage lung cancer (1)
-
early toxicity (1)
-
early-phase trials (1)
-
early-stage (3)
-
early-stage breast cancer (7)
-
early-stage cancer (1)
-
early-stage diagnosis (1)
-
early-stage disease (1)
-
ease of use (1)
-
Eastern Europe (1)
-
EBCTCG (1)
-
ebrt (1)
-
ECC 2015 (29)
-
ECCO (1)
-
ECCO 2015 (2)
-
ECHELON-1 trial (1)
-
ECHELON-2 (1)
-
ECOG (1)
-
ECOG 1505 (1)
-
ECOG ACRIN 2511 (1)
-
ECOG-ACRIN (1)
-
ecog-acrin 5508 (1)
-
Ed Giampietro (1)
-
edith a. perez (1)
-
Edith Perez (4)
-
Edmond Ang (1)
-
Edoardo Francini (1)
-
Eduardo Bruera (6)
-
Eduardo Cazap (4)
-
Eduardo L. Cazap (1)
-
Edvardas Kaminskas (1)
-
Edward Garon (1)
-
Edward George (1)
-
Edward Kim (1)
-
Edward Romond (1)
-
efficacy (3)
-
EFGR mutation (1)
-
EGFR (7)
-
EGFR inhibitor (1)
-
EGFR mutation (8)
-
EGFR positive (1)
-
EGFR resistance (1)
-
EGFR signaling (1)
-
EGFR T709M (1)
-
egfr tki (1)
-
EGFR+ NSCLC (1)
-
EHA25 Virtual (10)
-
Eileen Danaher Hacker (1)
-
Eileen M. O'Reilly (1)
-
Eileen O'Reilly (2)
-
elderly (1)
-
elderly patient (2)
-
elderly patients (1)
-
e-learning (1)
-
elective nodal irradiation (1)
-
Electra Paskett (4)
-
electronic medical records (1)
-
electronic support (1)
-
electronic symptom monitoring (1)
-
electronic tools (1)
-
electroporation (1)
-
Elena Elimova (1)
-
Eleni Efstathiou (1)
-
elevate tn (1)
-
elevated PSA (1)
-
Eli Lilly (1)
-
Elias Jabbour (1)
-
Elias Zahalka (1)
-
Eliezer Robinson (3)
-
Eliezer Van Allen (2)
-
Elihu Estey (2)
-
ELIZA A. HAWKES (1)
-
Elizabeth A. Comen (1)
-
Elizabeth Gerstner (1)
-
Elizabeth Kessler (1)
-
Elizabeth L. Travis (1)
-
Elizabeth Mittendorf (1)
-
Elizabeth Plimack (1)
-
Elizabeth Reed (1)
-
Elizabeth Shpall (1)
-
Elizabeth Simmons (1)
-
Ella Muller (1)
-
Ellen Miller-Sonet (1)
-
Ellen Sigal (4)
-
Ellin Berman (1)
-
ELOQUENT-2 (1)
-
elotozumab (1)
-
elotuzumab (3)
-
embryo (1)
-
emergency department (2)
-
emergency department costs (1)
-
emergency department use (1)
-
emergency surgery (1)
-
emerging therapies (1)
-
emetic (1)
-
emetogenic (2)
-
emetogenic chemotherapy (1)
-
Emil J. Freireich (3)
-
Emily A. Kuhl (3)
-
Emily Castellanos (1)
-
Emily Dumler (1)
-
Emily Haozous (1)
-
Emily Kuhl (21)
-
Emily Tonorezos (2)
-
Emily Zurbuchen (1)
-
Emma Hall (1)
-
Emory (1)
-
Emory Kinship Cancer Institute (1)
-
Emory University (11)
-
Emory University School of Medic (4)
-
emphysema (2)
-
EMR (1)
-
EMRs (1)
-
ENABLE model (1)
-
encequidar (1)
-
encorafenib (2)
-
end of life (5)
-
endocrine resistance (1)
-
endocrine side effects (1)
-
endocrine therapy (16)
-
endocrine therapy-resistant (1)
-
endocrine treatment (1)
-
endocrine-based therapy (1)
-
end-of-life (3)
-
end-of-life care (8)
-
end-of-life issues (1)
-
endometrial cancer (4)
-
EndoPredict (1)
-
endoscopy (1)
-
endothelial function (2)
-
enestop (1)
-
enfortumab vedotin (1)
-
ENGOT-OV16 NOVA (1)
-
ENGOT-OV16/NOVA (1)
-
enhanced quality (1)
-
Enrica Marchi (1)
-
Enrique Soto Perez-de-Celis (2)
-
enzaludamide (3)
-
enzalutamide (14)
-
EnzaMet (1)
-
enzamet trial (1)
-
EnzaRad (1)
-
EORTC (2)
-
EORTC 18071 (1)
-
EORTC 90101 CREATE (1)
-
epacadostat (1)
-
ePAL (1)
-
ependymoma (1)
-
epidemiology (1)
-
epidemiology in younger patients (1)
-
epirubicin (2)
-
epithelial ovarian cancer (5)
-
EPOCH-R (1)
-
eprirubicin (2)
-
equality (1)
-
ER visits (1)
-
ER+ (1)
-
ER+ breast cancer (5)
-
ER+ metastatic (1)
-
ER+/HER2– (1)
-
Erasmus University (1)
-
erectile function (1)
-
eribulin (1)
-
Eric Bouffet (1)
-
Eric Francois (4)
-
Eric Genden (1)
-
Eric Jonasch (3)
-
Eric Lax (1)
-
Eric Lim (2)
-
Eric Lis (1)
-
Eric M. Horwitz (1)
-
Eric Pujade-Lauraine (1)
-
Eric Roeland (10)
-
Eric S. Zhou (1)
-
Eric Van Cutsem (2)
-
Eric Winer (4)
-
Eric Wisotzky (1)
-
Erica Kaye (1)
-
Erica Mayer (2)
-
Erich Sturgis (1)
-
Erika Hamilton (1)
-
Erika Ramsdale (1)
-
Erin Hahn (2)
-
Erin Van Blarigan (1)
-
erlotinib (6)
-
Ernest Greenberg (2)
-
Ernest Hawk (3)
-
ER-positive (5)
-
ER-positive breast cancer (1)
-
ER-positive metastatic breast ca (1)
-
ESMO (28)
-
ESMO 16 (3)
-
ESMO 2015 (1)
-
ESMO 2016 (42)
-
ESMO 2017 (23)
-
ESMO 2018 (21)
-
esmo 2020 (20)
-
esophageal adenocarcinoma (1)
-
esophageal cancer (12)
-
esophageal carcinoma (1)
-
esophageal squamous cell carcino (1)
-
esophagectomy (2)
-
ESPAC-4 trial (1)
-
ESR1 mutation (1)
-
estrogen (1)
-
estrogen deprivation (1)
-
estrogen receptor (2)
-
estrogen receptor 1 (1)
-
estrogen receptor positive (3)
-
estrogen receptor-positive (9)
-
estrogen-receptor positive (2)
-
Ethan Basch (4)
-
Ethan Dmitrovsky (2)
-
ethics (2)
-
ethnicity (1)
-
Etienne Brain (1)
-
etoposide (2)
-
Eugene Tombler (6)
-
Eugenie Spiguel (4)
-
Eurocare (1)
-
Europe (1)
-
European Cancer Congress 2015 (1)
-
European Institute of Oncology (1)
-
European Medicines Agency (1)
-
European Myeloma Network Trial (2)
-
European Union (1)
-
euthanasia (1)
-
Eva Joseph (1)
-
Eva Pendleton (1)
-
Evan Lipson (2)
-
Evangelia Razis (1)
-
Everett Vokes (4)
-
everolimus (12)
-
evidence (1)
-
evidence-based (1)
-
Example (1)
-
exemestane (4)
-
exercise (4)
-
exercise intervention (1)
-
exercise oncology (1)
-
exome sequencing (1)
-
exon 14 (1)
-
exon 18 (1)
-
exon 19 (1)
-
exon 20 (1)
-
exon 21 (1)
-
exon skipping (1)
-
expanded access (2)
-
experimental treatment (1)
-
ExteNET trial (1)
-
extensive-stage sclc (1)
-
external beam (1)
-
external beam radiation (1)
-
external-beam radiation (1)
-
extrahepatic disease (2)
-
extreme hypofractionation (1)
-
EZH2 (1)
-
Ezra Cohen (1)
-
F. Owen Hoffman (5)
-
Fabiana Passoni (1)
-
Fabrice Barlesi (2)
-
Fabrice Denis (2)
-
facility volume (1)
-
FACP (1)
-
FACS trial (1)
-
FADI G. HADDAD (1)
-
FADILA KOUHEN (1)
-
Fadlo Khuri (1)
-
FALCON trial (1)
-
fallopian tube cancer (3)
-
familial cancer risk (1)
-
families (1)
-
family and patient outcomes (1)
-
family caregivers (1)
-
family centered care (1)
-
family history (1)
-
Farhad Ravandi (9)
-
FASCO (2)
-
FASCO; CLIFFORD A. HUDIS (1)
-
FAST trial (3)
-
fat (1)
-
fatigue (7)
-
fatigue score (1)
-
FATIMA REZZOUG (1)
-
Fatima Rizvi (1)
-
FC Rad Onc (SA) (1)
-
FCR (1)
-
FCS (SA) (1)
-
Fc-receptor polymorphism (2)
-
FDA (5)
-
FDA approval (1)
-
FDA approvals (1)
-
fda oncology center of excellence (1)
-
fear of recurrence (2)
-
fears (1)
-
feasibility (1)
-
febrile neutropenia (1)
-
FEC 100 (1)
-
federal government (2)
-
federal law (1)
-
Federico Cappuzzo (2)
-
female leadership (1)
-
female patients (1)
-
female survivors (1)
-
fergi trial (1)
-
FERGIE trial (1)
-
Fernando Diaz (1)
-
fertility (2)
-
fertility preservation (3)
-
fertility-sparing surgery (1)
-
fertility-sparing treatment (1)
-
fetal development (1)
-
FGFR (2)
-
FGFR inhibitor (1)
-
FGFR3 (1)
-
fibrosis (1)
-
Filippo Spreafico (1)
-
financial burden (1)
-
financial guidance (1)
-
financial intervention (1)
-
financial toxicities (1)
-
financial toxicity (3)
-
Fiona Damstra (1)
-
fire-3 trial (1)
-
first complete remission (1)
-
first study (1)
-
FIRSTANA (1)
-
first-line chemotherapy (1)
-
first-line hormone therapy (1)
-
first-line therapy (11)
-
first-line treatment (4)
-
FISH (1)
-
FISH data (1)
-
fitness (1)
-
fixed duration (1)
-
FLASH (1)
-
FLASH study (1)
-
Flatiron Health (1)
-
FLAURA (1)
-
flaura trial (1)
-
FLORIAN LORDICK (1)
-
Florida International University (1)
-
FLOT4-AIO trial (1)
-
FLT3 (2)
-
FLT3-ITD (1)
-
fludarabine (3)
-
fluoropyrimidine (2)
-
fluorouracil (5)
-
fnf-004 trial (1)
-
focus group (1)
-
FOLFIRI (1)
-
FOLFIRI-bevacizumab (2)
-
FOLFIRINOX (3)
-
FOLFOX (2)
-
folfoxiri (1)
-
follicular lymphoma (18)
-
follow-up care (1)
-
follow-up scans (1)
-
Forte trial (2)
-
FORWARD II (1)
-
fosaprepitant (2)
-
Fox Chase (6)
-
Fox Chase Cancer Center (7)
-
fractionation (3)
-
fractionation schedule (1)
-
frailty (1)
-
Fran Visco (1)
-
Francis Crick Institute (3)
-
Francis Lévi (1)
-
Francis Paul Worden (2)
-
Francis S. Collins (1)
-
Francisco J. Esteva (1)
-
Franck Morschhauser (1)
-
Franco Cavalli (1)
-
Franco Muggia (2)
-
Frank Sierawski (1)
-
Fred Hirsch (9)
-
Fred Hutch (2)
-
Fred Hutch Cancer Center (2)
-
Fred Hutchinson (5)
-
Fred Hutchinson Cancer Center (2)
-
Fred Hutchinson Cancer Research (1)
-
Fred Hutchinson Cancer Research Center (2)
-
Fred Huthinson (1)
-
Fred R. Hirsch (1)
-
Fred Saad (6)
-
Frederic Amant (2)
-
Frederic Grannis (1)
-
Frederic Ivan Leong Ting (1)
-
Frederick Appelbaum (3)
-
Frederick Behm (1)
-
Fredrick B. Hagemeister (1)
-
freedom from distant recurrence (1)
-
French FILO Group (1)
-
Fritz Schröder (2)
-
front-line treatment (1)
-
fulvestrant (12)
-
Fumiko Chino (1)
-
function ability (1)
-
futile care (1)
-
futile treatment (1)
-
G.S. Raju (1)
-
Gabriel Hortobagyi (2)
-
gabriel lopez (1)
-
Gabriele Roden (1)
-
Gabrielle Rocque (1)
-
GADOLIN (3)
-
Gail Flores (6)
-
GALLIUM trial (1)
-
gamma-1 study (1)
-
Ganesh Shankar (1)
-
gap in access (1)
-
GARTH STROHBEHN (1)
-
Gary Deng (9)
-
Gary H. Lyman (3)
-
Gary Onik (1)
-
Gary Rodin (1)
-
Gary Steele (1)
-
Gary Whitman (1)
-
Gary Winkel (1)
-
gastrectomy (1)
-
gastric adenocarcinoma (3)
-
gastric cancer (16)
-
Gastric Cancer (1)
-
gastric junction adenocarcinoma (1)
-
gastric junction cancer (1)
-
gastroesophageal adenocarcinoma (3)
-
gastroesophageal cancer (2)
-
Gastroesophageal Cancer (9)
-
gastroesophageal junction (1)
-
gastroesophageal junction adenoc (2)
-
gastroesophageal junction cancer (2)
-
gastrointestinal cancer (20)
-
Gastrointestinal Cancer (11)
-
gastrointestinal cancers (1)
-
Gastrointestinal Cancers Symposi (15)
-
gastrointestinal side effects (1)
-
gastrointestinal tract (1)
-
Gautam Mehta (1)
-
gBRCA mutation (1)
-
gc4419 (1)
-
G-CSF (1)
-
gefitnib (2)
-
geftinib (3)
-
GEJ adenocarcinoma (1)
-
gej cancer (3)
-
gemcitabine (18)
-
Gemelli University Hospital (1)
-
GEMOX (1)
-
GEN503 clinical trial (1)
-
gender (1)
-
gene alterations (1)
-
gene biomarkers (1)
-
Gene Bishop (1)
-
gene expression (3)
-
gene expression profiling (1)
-
gene recurrence score (2)
-
gene signature (1)
-
gene therapy (1)
-
gene-expression model (1)
-
generic drugs (1)
-
genetic alterations (1)
-
genetic information (1)
-
genetic mutation (1)
-
genetic mutations (2)
-
genetic phenotype (1)
-
genetic predisposition (1)
-
genetic sequencing (2)
-
genetic testing (3)
-
genetic variants (1)
-
genetics (12)
-
genitourinary cancer (17)
-
Genitourinary Cancers Symposium (35)
-
genitourinary oncology (1)
-
genome-wide sequencing (1)
-
genomic (1)
-
genomic alterations (2)
-
genomic analysis (2)
-
genomic characterization (1)
-
genomic data (1)
-
Genomic Health (1)
-
genomic profiling (2)
-
genomic risk (1)
-
genomic screening (1)
-
genomic sequencing (3)
-
genomic studies (1)
-
genomic test (1)
-
genomic testing (2)
-
genomic tests (1)
-
genomic therapy (1)
-
genomics (11)
-
Genomics/Genetics (7)
-
genotyping (1)
-
Geoffrey I. Shapiro (1)
-
Geoffrey Ku (1)
-
Geoffrey R. Oxnard (2)
-
George Bosl (1)
-
George Canellos (2)
-
George Sledge (2)
-
George Somlo (1)
-
George Washington University (2)
-
Georgetown (1)
-
Georgetown University (8)
-
Georgia Cancer Center (1)
-
GeparNuevo (1)
-
GeparSixto (1)
-
Geraldine Carroll (5)
-
Gerard Morton (1)
-
Gerdes (1)
-
Gerhardt Attard (1)
-
geriatric assessment (1)
-
geriatric assessments (1)
-
geriatric oncology (13)
-
Geriatric Oncology (2)
-
geriatric patients (2)
-
geriatric survivorship (1)
-
geriatrician (1)
-
geriatrics (1)
-
germ cell tumor (2)
-
German Breast Group (4)
-
germline BRCA mutation (1)
-
germline BRCA ovarian cancer (1)
-
germline mutation (3)
-
germline testing (1)
-
GETUG-AFU 16 (1)
-
Gevorg Tamamyan (1)
-
Ghassan Abou-Alfa (1)
-
GI cancer (3)
-
gi cancers symposium (26)
-
GI Cancers Symposium 2017 (18)
-
Gideon Blumenthal (2)
-
Gideon Michael Blumenthal (1)
-
Gilbert Lawrence (3)
-
Gilberto Lopes (3)
-
Gilead 115 (1)
-
gilteritinib (1)
-
Gini Fleming (1)
-
Giorgio Scagliotti (3)
-
Giuseppe Del Priore (1)
-
glasdegib (1)
-
Gleason score (1)
-
glioblastoma (2)
-
glioma (1)
-
global access (1)
-
global access to drugs (1)
-
global cancer burden (1)
-
global cancer care (3)
-
Global Cancer Care (2)
-
global cancer disparities (1)
-
global health (1)
-
global health care (1)
-
global health costs (1)
-
global oncology (2)
-
global qol (1)
-
global standards (1)
-
glottic cancer (1)
-
glycan (1)
-
glycochip (1)
-
glycomics (1)
-
gm-csf (1)
-
GOLD trial (1)
-
gonadotropin-releasing hormone a (1)
-
Gopal Gupta (1)
-
Gordon Schiff (1)
-
goserelin (1)
-
Gouri Shankar Bhattacharyya (1)
-
government healthcare (1)
-
Govind Persad (12)
-
GOYA trial (1)
-
Graall-R 2005 study (1)
-
Grace Wang (1)
-
grade (1)
-
grading tumors (1)
-
graft vs host disease (1)
-
graft-versus-host-disease (1)
-
graft-vs-host-disease (1)
-
Graham A. Colditz (2)
-
Graham Watson (1)
-
Grant Achatz (1)
-
Grant R. Williams (1)
-
gray zone lymphoma (2)
-
grbca (1)
-
Greg Judy (1)
-
Gregory Armstrong (4)
-
Gregory Bociek (1)
-
Gregory H. Jones (1)
-
Gregory Otterson (1)
-
Greta Stifel (1)
-
grey zone lymphoma (1)
-
gross total resection (1)
-
gu cancers symposium (16)
-
GU Cancers Symposium 2017 (21)
-
gu cancers symposium, 5FU, mitomycin, chemotherapy, radiation therapy, MIBC, muscle-invasive bladder cancer (1)
-
gu cancers symposium, cost of care, abiraterone, ADT, androgen-deprivation therapy, qol, survival, stampede trial (1)
-
gu cancers symposium, crpc, immunotherapy, tki, monoclonal antibody (1)
-
gu cancers symposium, doublet, triplet, RCC, kidney cancer, renal cell carcinoma, immunotherapy (1)
-
GU Symposium 2016 (18)
-
guadecitabine (1)
-
guidance statement (1)
-
guideline (1)
-
guidelines (6)
-
Guido Marcucci (1)
-
Guneet Walla (1)
-
Gunter von Minckwitz (5)
-
Gurpreet Rooprai (1)
-
Guru Sonpavde (1)
-
Gustave Roussy (11)
-
Guy’s and St. Thomas’ Hospital (1)
-
GVHD (3)
-
Gwendolyn Quinn (1)
-
gynecologic cancer (3)
-
gynecologic cancers (6)
-
Gynecologic Cancers (22)
-
H. Jack West (1)
-
H. Lee Moffitt Cancer Center (7)
-
h3b-8800 (1)
-
HAGAR ELGHAZAWY (1)
-
Hagop Kantarjian (24)
-
HAGOP M. KANTARJIAN (1)
-
hair loss (2)
-
hairy cell leukemia (1)
-
Haiti (1)
-
halting treatment (1)
-
Hamilton Health Sciences (1)
-
Hamza Hashmi (2)
-
handgrip test (1)
-
Hannah Dzimitrowicz (1)
-
Hannah Stewart (9)
-
Hans Gerdes (1)
-
Hans Wildiers (2)
-
Hans-Joerg Hammers (2)
-
haploidentical transplantation (1)
-
Harefield Hospital (1)
-
Harold Burstein (8)
-
Harold J. Burstein MD (1)
-
Harriet Gross (1)
-
Harry Bear (3)
-
harry d. bear (2)
-
Harry Erba (1)
-
Harvard Medical School (5)
-
Harvey J. Cohen (1)
-
Hassan Errihani (2)
-
HAYLEY ARCENEAUX (1)
-
HCC (6)
-
head and neck (1)
-
head and neck cancer (21)
-
Head and Neck Cancer (8)
-
head and neck cancers symposium (9)
-
head and neck melanoma (2)
-
head and neck squamous cell carcinoma (1)
-
head and neck symposium (1)
-
health care delivery research (1)
-
health care disparities (6)
-
health care provider (1)
-
health care utilization (1)
-
health disparities (2)
-
health justice (3)
-
health outcomes (1)
-
health system (1)
-
health technology (1)
-
health-care (5)
-
health-care application (1)
-
healthcare costs (1)
-
health-care costs (1)
-
healthcare delivery (1)
-
health-care delivery (1)
-
health-care policy (2)
-
Health-Care Policy (2)
-
healthcare system (1)
-
health-care technology (1)
-
heart disease (2)
-
heart dose (1)
-
Heather Greenlee (1)
-
HEATHER McARTHUR (1)
-
Heather Sook Han (1)
-
Heather Thompson Buum (1)
-
Heather Wakelee (4)
-
hedgehog pathway inhibitor (1)
-
Heiddis Valdimarsdottir (1)
-
Heidi Klepin (1)
-
Heikki Joensuu (1)
-
Heinz-Josef Lenz (6)
-
Helen Ma (1)
-
Helen MacKay (2)
-
Helper (1)
-
hematologic (1)
-
hematologic malignancies (7)
-
Hematologic Malignancies (5)
-
hematologic malignancy (3)
-
hematology (16)
-
hematopoietic cell transplantati (1)
-
Heniz-Josef Lenz (1)
-
Henry Ford Cancer Center (1)
-
Henry Ford Health (1)
-
Henry Lynch (1)
-
heparin-induced thrombocytopenia (1)
-
hepatobiliary cancer (3)
-
Hepatobiliary Cancer (9)
-
hepatocellular carcinoma (18)
-
her2 (1)
-
HER2- (2)
-
HER2 blockade (2)
-
HER2- breast cancer (3)
-
her2 low (1)
-
her2 mutations (1)
-
HER2 negative (3)
-
HER-2 negative (1)
-
HER2 positive (3)
-
HER2 status (1)
-
her2 tki (1)
-
HER2/neu gene (1)
-
HER2+ breast cancer (6)
-
her2climb (1)
-
HER2-directed therapy (1)
-
her2-e (1)
-
HER2-negative (23)
-
HER2-negative breast cancer (1)
-
HER2-positive (15)
-
HER2-positive breast cancer (6)
-
HER2-targeted treatment (1)
-
her3 (1)
-
hera trial (1)
-
HERACLES (1)
-
Herbert Irving Cancer Center (1)
-
hereditary breast cancer (1)
-
hereditary multigene panels (1)
-
hereditary test (1)
-
Hernan Barangan (1)
-
heterogeneity (2)
-
HFRT (1)
-
HGBCL (1)
-
HIF2A (1)
-
high quality care (1)
-
high risk of dying (1)
-
high tumor burden (1)
-
high-dose interferon-α2b (2)
-
high-dose methotrexate (2)
-
high-dose radiation (1)
-
high-dose radiotherapy (1)
-
high-grade B cell lymphoma (1)
-
high-grade serous ovarian cancer (1)
-
highlights (2)
-
high-risk (2)
-
high-risk breast cancer (2)
-
high-risk disease (2)
-
high-risk head and neck cancer (2)
-
high-risk lung cancer (2)
-
high-risk myeloma (1)
-
high-risk neuroblastoma (1)
-
high-risk node negative (1)
-
high-risk patients (1)
-
high-risk prostate cancer (5)
-
high-risk renal cell carcinoma (2)
-
high-volume centers (3)
-
high-volume prostate cancer (1)
-
Hilary Adams (4)
-
Hilary Gan (1)
-
Hillard Lazarus (2)
-
Hind Rafei (1)
-
hippocampus (1)
-
Hispanic (1)
-
Hispanic breast cancer (1)
-
histology (1)
-
history of addiction (1)
-
HIV (1)
-
HL (1)
-
hla (1)
-
HNSCC (3)
-
Hodgkin lymphoma (15)
-
Holger Lode (2)
-
Holly Lawson (1)
-
homeless patients (1)
-
homologous recombination deficiency (1)
-
Hong Kong (1)
-
HOPE CRAIG (13)
-
Hope Haefner (1)
-
Hope Rugo (12)
-
hope s. rugo (2)
-
hopelessness (1)
-
hopes (1)
-
Hôpital de Hautepierre (1)
-
Hôpital Henri Mondor (1)
-
Hôpital Hôtel-Dieu (1)
-
Hôpital Le Bocage (2)
-
Hôpital Saint-Antoine (1)
-
Hôpital Saint-Louis (2)
-
hormonal therapy (3)
-
hormone naive prostate cancer (1)
-
hormone receptive (1)
-
hormone receptor (1)
-
hormone receptor positive (6)
-
hormone receptor status (1)
-
hormone receptor-positive (7)
-
hormone receptor–positive (3)
-
hormone receptor-positive breast (1)
-
hormone replacement (1)
-
hormone status (1)
-
hormone therapy (2)
-
hormone therapy naive (1)
-
hormone treatment (1)
-
hormone-naive disease (1)
-
hormones (1)
-
hormone-sensitive (3)
-
hormonotherapy (1)
-
hospice (2)
-
hospice care (2)
-
hospice referrals (1)
-
hospital admission (1)
-
hospital readmission (1)
-
Hospital Universitario 12 De Oct (4)
-
hospitalizations (1)
-
hot flashes (2)
-
HOVON-Nordic Lymphoma Group (1)
-
Howard Burris (3)
-
Howard Chazin (1)
-
Howard Kaufman (1)
-
Howard Sandler (8)
-
Howard Scher (3)
-
Howard West (2)
-
HPV (9)
-
HPV vaccine (3)
-
HPV-16 (1)
-
HPV-16 vaccine (1)
-
HPV-associated oropharyngeal squ (1)
-
HPV-positive oropharyngeal cance (1)
-
HR positive (1)
-
HR+ (1)
-
HR+ breast cancer (3)
-
HR+/HER2- (1)
-
HR+/HER2+ (2)
-
HR-positive (6)
-
HR-positive breast cancer (2)
-
Humaid Al-Shamsi (1)
-
human error (1)
-
human leukocyte antigen (1)
-
human papillomavirus (9)
-
humanitarian (1)
-
Huntsman Cancer Institute (6)
-
hyaluronidase (1)
-
hydrogel spacer (1)
-
Hyo Jin Ru (1)
-
hyperglycemia (1)
-
hypertension (2)
-
hyperthermic intraperitoneal (1)
-
hyperthermic intraperitoneal che (1)
-
hyperthermic intraperitoneal chemotherapy (1)
-
hypocalcemia (1)
-
hypofractionated (5)
-
hypofractioned radiotherapy (4)
-
hypomethylating agent (1)
-
hypomethylating agents (1)
-
HYPO-RT-PC trial (1)
-
hypoxia (1)
-
hypoxia-inducible factor 2 alpha (1)
-
hyprofractioned radiation (1)
-
hysterectomy (1)
-
IAEA trial (1)
-
IALSC 2015 (2)
-
Ian Chau (1)
-
ian e. krop (1)
-
Ian Krop (2)
-
Ian Yarett (6)
-
IASLC 2015 (22)
-
ibandronate (3)
-
Ibiayi Dagogo-Jack (1)
-
IBIS-1 study (1)
-
ibis-i trial (1)
-
ibis-ii (1)
-
ibrutinib (17)
-
ibrutinib resistance (1)
-
Icahn Mount Sinai School of Medi (1)
-
Icahn School of Medicine (1)
-
iCanCare study (1)
-
icaria-mm (1)
-
ice trial (1)
-
ICLIO (3)
-
ICON6 trial (1)
-
ICON8 trial (2)
-
idarubicin (1)
-
IDEA collaboration (1)
-
IDEA trial (2)
-
IDEAL trial (1)
-
idelalisib (2)
-
idh1 (1)
-
IDMC (1)
-
IFCT-1501 MAPS2 trial (2)
-
ifofsamide (1)
-
IGF/insulin signaling (1)
-
IGFR (1)
-
Ignacio Melero (4)
-
IGRT (1)
-
IMAB362 (1)
-
image-guided (1)
-
image-guided radiotherapy (1)
-
imaging (2)
-
imaging technique (1)
-
imetelstat (1)
-
immediate surgery (1)
-
IMmotion 151 (3)
-
IMMU-132 (1)
-
immune biomarker (1)
-
immune cells (3)
-
immune checkpoint (2)
-
immune checkpoint blockade (3)
-
immune checkpoint blockers (1)
-
immune checkpoint inhibitor (2)
-
immune checkpoint inhibitors (10)
-
immune dysfunction (1)
-
immune inhibitors (1)
-
immune microenvironment (2)
-
immune response (2)
-
immune system (1)
-
immune therapies (1)
-
immune thrombocytopenia (1)
-
immune-related (1)
-
immune-related adverse events (2)
-
immunity (1)
-
immunochemotherapy (3)
-
immunogenic (2)
-
immunogenic MSI tumor (1)
-
immunohistochemistry (1)
-
immunology (2)
-
immunomodulatory agents (1)
-
immuno-oncology (19)
-
immunoregulatory inhibition (1)
-
immunoscore (1)
-
immunosignatures (1)
-
immunotherapeutics (1)
-
immunotherapies (1)
-
immunotherapy (169)
-
Immunotherapy (92)
-
immunotherpy (1)
-
IMO Clinique de Genolier (1)
-
IMPACT study (1)
-
IMpassion 130 (2)
-
Imperial College London (1)
-
IMpower 130 (1)
-
IMpower131 trial (1)
-
improved quality of life (1)
-
improved survival (1)
-
improved workflow (1)
-
improving cancer care (1)
-
improving outcomes (1)
-
IMPT (1)
-
IMRT (7)
-
imspire170 (1)
-
IMvigor (1)
-
IMvigor 211 (1)
-
imvigor130 (1)
-
IMvigor210 trial (1)
-
in situ vaccine (1)
-
in-breast recurrence (1)
-
inclusion criteria (2)
-
Indiana University (1)
-
Indiana University Simon Cancer (2)
-
individualized treatment (1)
-
indolent lymphoma (1)
-
indolent lymphomas (1)
-
indolent NHL (1)
-
indolent non-Hodgkin lymphoma (1)
-
induction (2)
-
induction BCG therapy (1)
-
induction chemotherapy (1)
-
induction radiotherapy (1)
-
induction therapy (2)
-
induction treatment (1)
-
inequality of care (1)
-
infectious disease (2)
-
inflammation (2)
-
inflammatory breast cancer (2)
-
infrastructure (1)
-
Inga Lennes (1)
-
Ingrid Mayer (3)
-
inhibitory receptor expression (1)
-
initial therapy (2)
-
inotuzumab (2)
-
inotuzumab ozogamicin (1)
-
INSERM (4)
-
insomnia (2)
-
Institut Curie (1)
-
Institut Curies (1)
-
Institut Gustave Roussy (8)
-
Institut Jules Bordet (1)
-
Institut Régional du Cancer (1)
-
Institute for Clinical Evaluativ (1)
-
Institute of Cancer Research (3)
-
Institute of Cancer Research Lon (1)
-
Institute of Clinical Cancer Res (1)
-
Institute of Medicine (1)
-
Institute of Medicine report (1)
-
Instituto Nazionale Tumori-Fonda (2)
-
insulin (1)
-
insurance (1)
-
integrated care (1)
-
integrating palliative care (1)
-
integration of palliative care (2)
-
intensity modulated proton thera (1)
-
intensity-modulated (1)
-
intensity-modulated radiotherapy (1)
-
intensive chemotherapy (1)
-
interaperitoneal (1)
-
interferon gamma (1)
-
interleukin 12 (1)
-
intermediate-risk (2)
-
intermediate-risk prostate cance (1)
-
international oncology (3)
-
international standards (1)
-
interpretation (1)
-
intervention (1)
-
interventional (1)
-
intracranial disease (1)
-
intracranial response (2)
-
intraoperative peritoneal lavage (1)
-
intraperitoneal (1)
-
intraperitoneal chemotherapy (2)
-
intraperitoneal immunotherapy (1)
-
intratumoral (1)
-
intravascular DLBCL (1)
-
intravenous (1)
-
intravenous chemotherapy (2)
-
intrinsic expression subtype (1)
-
invasive breast cancer (2)
-
investigator-choice chemotherapy (1)
-
involved field irradiation (1)
-
ipatasertib (1)
-
ipilimumab (27)
-
ipilimumab-refractory (1)
-
ipilumumab (5)
-
IPOS APOS 2015 (6)
-
IPOS-APOS 2015 (11)
-
IPOS-APOS 2015. Andrea Patenaude (1)
-
Ira Byock (1)
-
Irad Deutsch (1)
-
iRAE (2)
-
Irene Higginson (2)
-
irinotecan (4)
-
IROCK study (1)
-
ISA101 (1)
-
Isabel Arrellaga-Romany (1)
-
Isacco Montroni (1)
-
isatuximab (1)
-
ischemic stroke (1)
-
Ishwaria M. Subbiah (1)
-
Ismail Jatoi (3)
-
Issues in Oncology (18)
-
Istituto Nazionale dei Tumori (4)
-
Istituto Toscano Tumori-Ospedale (1)
-
italy (1)
-
iv paclitaxel (1)
-
ivosidenib (1)
-
IVY DUNEIER (1)
-
IWWD.org (1)
-
ixabepilone (1)
-
ixazomib (3)
-
J. Gregory Mears (1)
-
J. Nicholas Dionne-Odom (1)
-
Jaafar Bennouna (1)
-
Jacek Jassem (2)
-
Jack B. Fu (1)
-
Jack Cuzick (4)
-
Jack Gentile (1)
-
Jack Lambert (1)
-
Jacob Laubach (1)
-
Jacob Rowe (1)
-
Jacob Strand (1)
-
Jaffer Ajani (2)
-
JAK inhibitor (2)
-
JAK2 inhibitor (1)
-
Jame Abraham (21)
-
James A. Stewart (1)
-
James Abbruzzese (3)
-
James Armitage (26)
-
James Armitage Hagop Kantarjian (1)
-
James Berenson (1)
-
James Cancer Center (1)
-
James Cancer Hospital (1)
-
James Cleary (1)
-
James Doroshow (2)
-
James F. Holland (3)
-
James Foran (2)
-
James Gould (1)
-
James Hillard (1)
-
James Jett (2)
-
James Kochenderfer (4)
-
James Mohler (1)
-
James Mulshine (10)
-
James O. Armitage (3)
-
James P. Stevenson (1)
-
James Perry (1)
-
James Rubenstein (1)
-
James Smithy (1)
-
James W. Lynch (1)
-
James Yu (2)
-
Jamie H. Von Roenn (1)
-
Jamie Jacobs (1)
-
Jamil Aliyev (1)
-
Jamil Rivers (1)
-
Jan Buckner (2)
-
Jan Oosterwijk (1)
-
Jane Greene (1)
-
Jane Gutkovich (2)
-
Jane McNeil Beith (1)
-
Jane Winter (1)
-
Janessa Laskin (1)
-
Janet Klein (1)
-
Janet Snapp (1)
-
Janet Weinberg (1)
-
Janet Wohlmacher (1)
-
Janice Dutcher (1)
-
Janine Overcash (5)
-
Japan Clinical Oncology Group (1)
-
Jasenka Piljac Žegarac (9)
-
Jasmine M. Wong (1)
-
Jason Gotlib (1)
-
Jason Zimmermann (1)
-
JAVELIN (1)
-
javelin renal 101 (1)
-
JAVELIN study (1)
-
Javier Cortes (1)
-
Jay Harris (5)
-
Jay R. Harris (1)
-
JCOG1001 (1)
-
JD (1)
-
Jean Connors (1)
-
Jean M. Connors (5)
-
Jean-Charles Soria (6)
-
Jean-Michel Hannoun-Levi (1)
-
JEANNETTE PARKES (1)
-
Jeannine Nonaillada (1)
-
Jeannine Walston (1)
-
Jean-Yves Douillard (2)
-
Jedd Wolchok (6)
-
Jeff Boyd (1)
-
Jeff Dunn (4)
-
Jeff Summers (1)
-
Jeffrey Bradley (1)
-
Jeffrey Crawford (1)
-
Jeffrey Groeger (1)
-
Jeffrey Jones (1)
-
Jeffrey Lancet (1)
-
Jeffrey Patton (1)
-
Jeffrey Schneider (1)
-
Jeffrey Weber (1)
-
Jennifer Brown (2)
-
Jennifer Brudno (1)
-
Jennifer Gao (1)
-
Jennifer Ho (1)
-
Jennifer King (2)
-
Jennifer Legible (1)
-
Jennifer Ligibel (2)
-
Jennifer Litton (1)
-
Jennifer Lycette (2)
-
Jennifer Mack (1)
-
Jennifer Nam Choi (1)
-
Jennifer Temel (4)
-
Jennifer Titche (1)
-
Jennifer Wargo (1)
-
Jennifer Woyach (4)
-
Jenny Ahlstrom (1)
-
Jens Huober (1)
-
Jenske Geerling (1)
-
Jeong-Seon Ryu (1)
-
Jerald Radich (5)
-
Jerald Varner (1)
-
Jeremy Hirst (1)
-
Jeremy Hon (1)
-
Jeremy Pivor (1)
-
Jeremy Warner (1)
-
Jeri Dyson (1)
-
Jerome Yates (1)
-
Jeromie Ballreich (1)
-
Jesse McGreivy (1)
-
Jessica Boehmer (1)
-
Jessica Nye (1)
-
Jessica Scott (2)
-
Jessica Wu (1)
-
Jesuel Padro-Guzman (1)
-
Jill Lacy (1)
-
Jim Armitage (2)
-
Jim Mulshine (1)
-
Jim Omel (2)
-
Jim Taulman (1)
-
Jim Turner (1)
-
Jimmie Harvey (1)
-
Jimmie Holland (7)
-
Jinane Kharmoum (1)
-
jipang trial (1)
-
jo (1)
-
Jo Cavallo (1106)
-
Joachim Yahalom (1)
-
Joanne Mortimer (2)
-
Joanne Weidhaas (1)
-
Jocelyn Ray (1)
-
Jocelyn Solis-Moreira (2)
-
Jodi MacLeod (1)
-
Joel Tepper (2)
-
John A. Thompson (1)
-
John Cox (2)
-
John F. Thompson (1)
-
John Fracchia (1)
-
John Gentile Jr (1)
-
John Gerecitano (2)
-
John Goodman (2)
-
John Grecula (2)
-
John Gribben (1)
-
John H. Stewart (1)
-
John Hainsworth (1)
-
John Jakob (1)
-
John L. Marshall (1)
-
John Leonard (2)
-
John Macdonald (1)
-
John Marshall (10)
-
John Neoptolemos (1)
-
John Pagel (2)
-
John Peters (1)
-
John Primrose (1)
-
John Smyth (12)
-
John Suh (1)
-
John Thompson (1)
-
John Williams (1)
-
JOHNNY BORGSTROM (1)
-
Johns Hopkins (6)
-
Johns Hopkins Bloomberg School o (1)
-
Johns Hopkins Kimmel Cancer Center (1)
-
Johns Hopkins Medicine (1)
-
Johns Hopkins School of Medicine (1)
-
Johns Hopkins Sidney Kimmel Cancer Center (1)
-
Johns Hopkins University (3)
-
Joke Bradt (2)
-
Joleen Hubbard (1)
-
Jonas de Souza (1)
-
Jonathan Cohen (1)
-
Jonathan Cotliar (2)
-
Jonathan Friedberg (3)
-
Jonathan L. Finlay (1)
-
Jonathan Ledermann (2)
-
Jonathan Lewis (1)
-
Jonathan R. Strosberg (1)
-
Jonathan Rosenberg (5)
-
Jonathan Schwartz (3)
-
Jonathan Strosberg (2)
-
JONATHAN W. FRIEDBERG (1)
-
Jonathon Cohen (2)
-
Jordan Holmes (1)
-
Jorg Dietrich (1)
-
Jorge Cortes (3)
-
Jorge Reis-Filho (1)
-
Jose Karam (1)
-
Jose Leis (1)
-
Josep Llovet (2)
-
Joseph B. Narus (1)
-
Joseph Bailes (1)
-
Joseph Connors (3)
-
Joseph Cupolo (1)
-
Joseph Greer (1)
-
Joseph Jacobson (2)
-
Joseph Mason (1)
-
Joseph Simone (1)
-
Joseph Sparano (4)
-
Joseph V. Simone (1)
-
Joseph V. Simone Award (2)
-
Josh Mailman (1)
-
Joshua Armenia (1)
-
Joshua Brody (1)
-
Joshua Drago (1)
-
Joshua Lang (1)
-
Joshua Spendlove (1)
-
JOYCE KURISKO (1)
-
Joyce Liu (2)
-
Jr (1)
-
Juan Chipollini (1)
-
Juanita Crook (1)
-
Judd Moul (1)
-
Judith Balmana (2)
-
Judith Malmgren (1)
-
Judith Paice (3)
-
Judith Vick (2)
-
Judy Garber (5)
-
Judy Perkins (1)
-
Jules Bordet Institute (2)
-
Julia Fehniger (1)
-
Julia Rowland (2)
-
Julia White (2)
-
Julie A. Schneider (1)
-
Julie Bryar Porter (1)
-
Julie Bullock (1)
-
Julie Gralow (6)
-
Julie Lemieux (2)
-
julie m. vose (3)
-
Julie Miller (1)
-
Julie Nangia (1)
-
Julie Park (1)
-
Julie Silver (1)
-
Julie Vose (34)
-
Julien Edeline (2)
-
Julienne Bower (1)
-
JULIET trial (1)
-
Jun J. Mao (5)
-
Jun Mao (13)
-
Jung-min Lee (1)
-
Justin Brown (1)
-
Justin Gainor (1)
-
Jyothirmai Gubili (71)
-
K. Holly Mead (1)
-
K. Simon Yeung (2)
-
Kah Poh (Melissa) Loh (2)
-
Kah Poh Melissa Loh (1)
-
Kaiser Permanente (1)
-
Kamal Menghrajani (1)
-
Kamran Ahmed (1)
-
Karen Colbert Maresso (1)
-
Karen Daily (1)
-
KAREN E. KNUDSEN (1)
-
Karen Fasciano (2)
-
Karen J. Krag (1)
-
Karen Kelly (3)
-
Karen Knudsen (1)
-
Karen Lisa Smith (2)
-
Karen Marcus (1)
-
Karen Merlino (1)
-
Karen Nestor (1)
-
Karen Peterson (1)
-
Karen Popkin (4)
-
Karen Reckamp (1)
-
Karen Winkfield (1)
-
Karim Chamie (1)
-
Karim Fizazi (4)
-
Karim Touijer (1)
-
Karl Lewis (1)
-
Karl Schwartz (2)
-
Karuna Ganesh (1)
-
Karyn Goodman (1)
-
Katarzyna Jerzak (1)
-
kate2 (1)
-
Katharina Fleischhauer (2)
-
Katherine Crawford (2)
-
Katherine Crew (1)
-
Katherine H. Crawford (2)
-
Katherine Reeder-Hayes (2)
-
KATHERINE trial (1)
-
Kathleen Bickel (1)
-
Kathleen Cathcart (1)
-
Kathleen Elizabeth Bickel (1)
-
Kathleen Foley (2)
-
Kathleen Moore (2)
-
Kathleen Pritchard (2)
-
Kathleen Ruddy (1)
-
Kathleen Uhl (1)
-
Kathleen Wesa (5)
-
Katholieke Universiteit Leuven (1)
-
Kathryn Desimone (1)
-
Kathryn E. Hitchcock (1)
-
Kathryn Hudson (1)
-
Kathryn Mileham (1)
-
Kathryn Roberts (1)
-
Kathryn Ruddy (1)
-
Kathryn Sommer (1)
-
Kathy Albain (2)
-
Kathy Giusti (3)
-
Kathy Holliman (2)
-
Kathy Miller (1)
-
Katie Greenzang (1)
-
Katja Wiesel (2)
-
Kavita Dharmarajan (1)
-
Kavita Mishra (1)
-
Kavita Yadav (2)
-
Keegan Bales (9)
-
Keith Flaherty (2)
-
keith mccrae (6)
-
Kelly Cotton (1)
-
KELLY HEWITT (1)
-
Kelly Trevino (1)
-
Ken Anderson (1)
-
Keneene Lewis (1)
-
Kenneth Anderson (10)
-
Kenneth Foon (1)
-
Kenneth L. Kehl (1)
-
Kenneth R. Adler (1)
-
Kerin Adelson (2)
-
Kerri Winters-Stone (2)
-
Kevin B. Knopf (1)
-
Kevin Knopf (1)
-
Kevin Krull (1)
-
Kevin Liou (2)
-
Kevin Oeffinger (3)
-
KEVIN T. LIOU (2)
-
Kevin Weinfurt (1)
-
KEYNOTE 014 (1)
-
keynote 119 (1)
-
keynote trial (2)
-
KEYNOTE trials (1)
-
KEYNOTE-001 (2)
-
KEYNOTE-002 (1)
-
KEYNOTE-028 (2)
-
KEYNOTE-028 study (1)
-
KEYNOTE-042 (1)
-
KEYNOTE-045 (1)
-
KEYNOTE-045 trial (1)
-
keynote-048 (1)
-
KEYNOTE-052 (1)
-
KEYNOTE-057 (1)
-
keynote-062 (1)
-
keynote-158 (1)
-
keynote-181 (1)
-
KEYNOTE-224 (1)
-
keynote-426 (2)
-
KEYNOTE-427 (2)
-
keynote-522 (1)
-
Khalid El Bairi (5)
-
Khalid El Bairi, Dounia Filali, Nabil Ismaili, Zouhour Bourhaleb, Ali Sbai, Mohamed Marjani, Zineb Benbrahim, Meriem Iraqi Houssaini, Mohamed Mesmoudi (1)
-
Khalid Halahleh (1)
-
Khalid Rehman (3)
-
kidney cancer (54)
-
Kidney Cancer (15)
-
Kids v Cancer (1)
-
Kieron Dunleavy (4)
-
killer-cell Ig-like receptor gen (2)
-
Kim A. Margolin (1)
-
Kim Leary (1)
-
Kim Polacek (1)
-
Kimberley Lee (1)
-
Kimberley T. Lee (1)
-
Kimberly Boldig (1)
-
Kimmie Ng (3)
-
kinase targets (1)
-
kindly cancer (3)
-
Kings College Hospital (1)
-
Kirby Lewis (1)
-
Kirsten Boyd Goldberg (14)
-
Kishore Dass (1)
-
Kishwer Nehal (1)
-
KLAUS PUSCHEL (1)
-
Koh (1)
-
Konrad Stopsack (1)
-
Koshy Alexander (1)
-
Krankenhaus Nordwest (1)
-
KRAS (3)
-
KRAS mutations (1)
-
Krishna Gundabolu (1)
-
Krishnansu Tewari (2)
-
Kristen Spencer (1)
-
Kristen Whitaker (1)
-
kristine trial (1)
-
Krzysztof Bujko (2)
-
Kwok-Leung Cheung (1)
-
Kyle Rove (1)
-
L. Elizabeth Budde (2)
-
L. Jeffrey Medeiros (19)
-
L. Michael Glode (1)
-
lack of medical resources (1)
-
lack of resources (1)
-
Lacouture (1)
-
Lancaster General Hospital (1)
-
Lanie Brewster Quinn (1)
-
laparoscopic (2)
-
lapatinib (4)
-
Lara Benusis (2)
-
large B cell lymphoma (1)
-
large cell neuroendocrine lung t (1)
-
larotrectinib (1)
-
Larry Leichman (1)
-
Larry Rosenberg (5)
-
Larry Slavens (1)
-
Larry Weisenthal (3)
-
Larry Wickerham (2)
-
laryngeal cancer (1)
-
laryngeal preservation (1)
-
late effects (3)
-
late recurrence (1)
-
late side effects (1)
-
late stage melanoma (1)
-
late toxicity (1)
-
late-stage cancer (2)
-
late-stage colon cancer (1)
-
Latin America (1)
-
Latino breast cancer (1)
-
LATITUDE trial (4)
-
Laura A. Levit (1)
-
Laura Esserman (1)
-
Laura Greco (1)
-
LAURA J. ESSERMAN (1)
-
Laura Leavit (1)
-
Laura Melton (1)
-
Laura Panattoni (1)
-
Laura Q.M. Chow (1)
-
Laura Rooms (1)
-
Laura Veneroni (1)
-
Laura Williams Goff (1)
-
Lauren Davis (3)
-
Lauren Hotaki (1)
-
Lauren Wallner (1)
-
Laurence H. Baker (4)
-
Laurie Gaspar (1)
-
Laurie Helen Sehn (1)
-
Laurie Lyckholm (1)
-
Laurie MacCaskill (1)
-
Laurie Sehn (14)
-
law (3)
-
Lawrence Einhorn (6)
-
Lawrence Feldman (1)
-
Lawrence Fong (1)
-
Lawrence Shulman (5)
-
Leah Christl (1)
-
Leah Lawrence (11)
-
lean body mass (3)
-
Lee Jones (1)
-
Lee Krug (1)
-
Lee Newcomer (4)
-
Lee Schwartzberg (11)
-
Leena Gandhi (1)
-
left side tumor (1)
-
left ventricular ejection fratio (1)
-
legal issues (2)
-
Legislation (2)
-
Leiden University Medical Center (1)
-
Leiden University Medical Centre (1)
-
Leigh Leibel (1)
-
leiomyosarcoma (2)
-
Leisha Emens (1)
-
lenalidomide (22)
-
lenaliodmide (1)
-
length of treatment (1)
-
lenvatinib (4)
-
Leo Gordon (3)
-
Leonard Berry (1)
-
Leonard Gunderson (2)
-
Leonard Saltz (5)
-
Leonard Zwelling (1)
-
Leora Horn (2)
-
Lesa Kirkman (1)
-
lethal prostate cancer (2)
-
letrozole (9)
-
leucovorin (2)
-
leukemia (42)
-
Leukemia (16)
-
Levine Cancer Institute (5)
-
levothyroxine (1)
-
Lewis Foxhall (2)
-
Lewis Roberts (1)
-
lgbtq (2)
-
LGBTQ patients (1)
-
LHRH agonists (1)
-
Lia Halasz (1)
-
Libia Scheller (1)
-
Lida Zheng (1)
-
Lidia Schapira (2)
-
life expectancy (1)
-
Life Interrupted (1)
-
lifestyle (1)
-
lifestyle change (1)
-
lifestyle recommendations (1)
-
limited-stage disease (1)
-
Limo Chen (1)
-
Linda Burns (2)
-
Linda Carlson (5)
-
linda j. burns (6)
-
Linda McDonald (1)
-
Linda T. Vahdat (1)
-
Linda Van Le (1)
-
Lindi Campbell (1)
-
Linnea Olson (1)
-
liposome (1)
-
liquid biopsy (3)
-
lisa a. carey (3)
-
Lisa Arzola (1)
-
Lisa Carey (25)
-
Lisa Carey MD (1)
-
Lisa DeAngelis (1)
-
Lisa Diller (3)
-
Lisa Marie Ruppert (1)
-
Lisa Mendelson (1)
-
Lisa Newman (1)
-
Lisa Diller (1)
-
lisocabtagene maraleucel (1)
-
Lital Keinan-Boker (2)
-
liver cancer (15)
-
liver metastases (6)
-
liver SBRT (1)
-
liver-directed therapy (1)
-
living with cancer (1)
-
Liz Janetschek (84)
-
Liz Janetschek Pasini (5)
-
Liz Pasini (16)
-
Liza Marshall (1)
-
local control (4)
-
local disease (2)
-
local recurrence (1)
-
local therapy (1)
-
localized disease (1)
-
localized high risk (1)
-
localized prostate cancer (4)
-
localized rectal cancer (1)
-
locally advanced (2)
-
locally advanced breast cancer (3)
-
locally advanced cancer (1)
-
locally advanced disease (1)
-
locally recurrent breast cancer (1)
-
locoregional (1)
-
locoregional treatment (4)
-
locoregionally recurrent breast (1)
-
Lodovico Balducci (9)
-
Lois Ramondetta (1)
-
Lombardi Cancer Center (4)
-
lomustine (1)
-
London Health Sciences Centre (1)
-
long-term ADT (1)
-
long-term morbidity (1)
-
long-term mortality (1)
-
long-term overall survival (1)
-
long-term results (1)
-
long-term sequelae (1)
-
long-term side effects (1)
-
long-term survival (2)
-
long-term therapy (1)
-
Lora Thompson (1)
-
Lorenzo Cohen (6)
-
Lori Alf (1)
-
Lori Goldstein (2)
-
Lori J. Wirth (1)
-
Lori Pierce (6)
-
Lori Wiener (4)
-
Lori Wirth (3)
-
Loriana Hernandez-Aldama (1)
-
Lorraine Egan (1)
-
Lorraine McEvoy (1)
-
Lorraine Pelosof (2)
-
Los Angeles (1)
-
loss (1)
-
loss of a child (1)
-
loss of dignity (1)
-
loss of muscle (1)
-
LOTUS trial (1)
-
Lou Vaickus (1)
-
Louis Burt Nabors (1)
-
Louis Harrison (1)
-
Louis Staudt (1)
-
Louise Cooper (1)
-
low dose screening (1)
-
low HER2-expressing (1)
-
low income country (1)
-
low resource setting (1)
-
low-dose chemotherapy (2)
-
low-dose CT (1)
-
low-dose CT screening (1)
-
Lowell Kleinman (1)
-
lower gastrointestinal cancer (1)
-
lower mortality (1)
-
lower-income patients (1)
-
low-fat diet (2)
-
low-grade glioma (1)
-
low-income (2)
-
low-income country (1)
-
low-literacy patients (1)
-
low-risk (2)
-
low-risk prostate cancer (1)
-
low-value care (1)
-
low-volume prostate cancer (1)
-
Loyola University Medical Center (1)
-
Lu Daopei Hospital (1)
-
Lu-177 dotatate (1)
-
Lucas Dean (1)
-
Luciano Costa (2)
-
Lucy Pickard (1)
-
Ludwig Maximilian University of Munich (2)
-
Luis A. Diaz (1)
-
Luis Alejandro Salicrup (1)
-
Luis E. Pino (2)
-
LUIS EDUARDO PINO VILLARREAL (1)
-
Luis Meza (1)
-
Luis Paz-Ares (6)
-
Lukas Wartman (1)
-
luminal A (1)
-
luminal type breast cancer (1)
-
lumpectomy (3)
-
lung cancer (121)
-
Lung Cancer (43)
-
Lung Cancer Alliance (1)
-
lung cancer risk (1)
-
lung cancer screening (3)
-
lung cancer staging (1)
-
lung cancer workup (1)
-
lung dose (1)
-
lung toxicity (1)
-
LungenClinic (3)
-
LUNGMAP (1)
-
lupus (1)
-
lurbinectedin (3)
-
Lurie Comprehensive Cancer Cente (1)
-
luspatercept (1)
-
LUX-Lung 7 Trial (2)
-
LUX-Lung 8 (1)
-
LY2606368 (1)
-
LYDIA CAIRNCROSS (1)
-
LyMa trial (2)
-
lymph node (2)
-
lymph node assessment (1)
-
lymph node dissection (2)
-
lymph node surgery (1)
-
lymph nodes (1)
-
lymphadenectomy (2)
-
lymphedema (1)
-
lymphoblastic leukemia (1)
-
lymphocytes (1)
-
lymphocytic infiltration (1)
-
lymphoid malignancies (2)
-
lymphoma (72)
-
Lymphoma (19)
-
lymphoma survivors (1)
-
lymphomas (1)
-
lymphoplasmacytic lymphoma (1)
-
lynch syndrome (1)
-
Lynda Balneaves (1)
-
Lynn Cancer Institute (1)
-
Lynn Sage Comprehensive Breast C (1)
-
LYNN SCHUCHTER (1)
-
Lynn Volk (1)
-
Lynne Lederman (1)
-
Lysa Remarc Study (1)
-
Lysa Remarc trial (1)
-
Lysa study (2)
-
M D Anderson (1)
-
M. Catherine Pietanza (2)
-
M. Gregg Bloche (1)
-
M. Shaalan Beg (1)
-
M. Steven Piver (2)
-
MA20 (1)
-
Mace Rothenberg (1)
-
Mafalda Von Alvensleben (1)
-
magnetic resonance imaging (2)
-
Maha Hussain (5)
-
Mahmoud Al-Hawary (1)
-
MAIA trial (1)
-
maintenance (1)
-
maintenance BCG therapy (1)
-
maintenance monotherapy (1)
-
maintenance therapy (5)
-
Mairéad Geraldine McNamara (1)
-
Maki Tania (1)
-
male patients (1)
-
Malgorzata Mikulska (1)
-
mammography (2)
-
mammography guidelines (1)
-
management of lung cancer (1)
-
Managing Editor (1)
-
managing toxicities (1)
-
Manali Patel (2)
-
Mani Menon (1)
-
Manish Shah (1)
-
Manisha H. Shah (1)
-
Manisha Shah (2)
-
Mansoor Mirza (1)
-
Mansoor Raza Mirza (2)
-
mantle cell (1)
-
mantle cell lymphoma (11)
-
Manuel Hidalgo (1)
-
Manuj Agarwal (3)
-
Marc Lawler (1)
-
Marc R. Theoret (1)
-
Marc Theoret (1)
-
Marc Ychou (1)
-
Marcel Rozencweig (1)
-
Marcel Verheij (1)
-
Marci Greenberg Cox (1)
-
Marcus Randall (1)
-
Margaret A. Tempero (1)
-
Margaret Callahan (1)
-
Margaret Hamburg (1)
-
Margaret Kasner (1)
-
Margaret O’Donnell (1)
-
Margaret O'Donnell (1)
-
Margaret Tempero (3)
-
Margaret von Mehren (2)
-
Margaret Werts (1)
-
margetuximab (2)
-
marginal zone lymphoma (1)
-
Margot Fromer (2)
-
Margot J. Fromer (55)
-
Maria Cabanillas (1)
-
Maria Clemence Schwaederle (1)
-
Maria Sklodowska Curie Cancer Ce (1)
-
Maria Werner-Wasik (2)
-
Mariame Chraibi (1)
-
Mariana Figueiro (1)
-
Marie Bleakley (1)
-
Marie Elaine Price-Lockridge (1)
-
Marie Krejci (1)
-
Marie Sabo Recine (6)
-
Marie-Andree Forget (1)
-
Mario E. Lacouture (6)
-
Mario Sznol (4)
-
marital status (1)
-
Marjory Charlot (1)
-
Mark Helvie (1)
-
Mark Lazenby (2)
-
Mark Lewis (1)
-
Mark McCamish (1)
-
Mark R. Gilbert (1)
-
Mark Ratain (3)
-
Mark Robson (2)
-
Mark Roschewski (2)
-
Mark Smith (1)
-
Mark Talamonti (1)
-
Mark Trombetta (1)
-
marker decline (1)
-
Marleen Kok (1)
-
Marlise R. Luskin (1)
-
Marseille Cancer Center (2)
-
Marsha Axler (1)
-
Marsha Edwards (1)
-
Martee Hensley (1)
-
Martha Donoghue (1)
-
Martha Tracy (1)
-
Martin Edelman (1)
-
Martin Reck (2)
-
Martin Schrappe (2)
-
Martin Schuler (2)
-
Martin Tallman (3)
-
Martin Van Den Vent (1)
-
Martine Extermann (1)
-
Martine Frouws (2)
-
Martine Piccart (1)
-
Martine Piccart-Gebhart (5)
-
Marvin Stone (1)
-
Marwan Fakih (1)
-
MARY ALMA WELCH (1)
-
Mary B. Daly (1)
-
Mary Bridge Children's Hospital (1)
-
Mary Evelyn Burman (1)
-
Mary Gospodarowicz (6)
-
Mary Longhini (1)
-
Mary Lou Smith (2)
-
Mary McCabe (6)
-
MARY MULCAHY (1)
-
Mary Pasquinelli (1)
-
Mary Vargo (1)
-
Masanori Terashima (1)
-
Mass Gen (2)
-
Massachusetts General (7)
-
Massachusetts General Hospital (14)
-
massage (1)
-
Massimo Cristofanilli (2)
-
mastectomy (5)
-
MATCH trial (1)
-
Matt Ellefson (1)
-
Matt Kalaycio (1)
-
Matt Lunning (1)
-
Matteo Lambertini (3)
-
Matteo Silva (1)
-
Matthew Ellis (6)
-
Matthew Galsky (1)
-
Matthew Goetz (1)
-
Matthew Hellmann (1)
-
matthew j. ellis (1)
-
Matthew J. Resnick (1)
-
Matthew Loscalzo (2)
-
matthew lunning (5)
-
Matthew Smith (2)
-
Matthew Stenger (4214)
-
MATTHEW ZIBELMAN (1)
-
Matti Aapro (7)
-
Maura Dickler (3)
-
Maura Gillian (1)
-
Maura Gillison (2)
-
Maura Massimino (1)
-
Maureen Markham (1)
-
Maureen Roberts (1)
-
Maurie Markman (2)
-
MAVERICC study (2)
-
Maximilian Diehn (1)
-
Maxwell Krem (1)
-
Mayo Clinc Cancer Center (3)
-
Mayo Clinic (35)
-
Mazie Tsang (1)
-
MBA (1)
-
MBBCh (1)
-
mbc (1)
-
MBChB (1)
-
mcc (1)
-
McGill (3)
-
mcguire lecture (1)
-
MCL (6)
-
McMaster University (2)
-
mcrc (1)
-
mcrpc (1)
-
MD (12)
-
MD Abdul Wadud Khan (1)
-
MD Anderson (23)
-
MD Anderson Cancer Center (14)
-
MD; Lola Fashoyin-Aje (1)
-
MD; Marc R. Theoret (1)
-
MD; Martha B. Donoghue (1)
-
MD; Paul G. Kluetz (1)
-
MD; Richard Pazdur (1)
-
MDS (5)
-
meaning centered psychotherapy (4)
-
meaning centered therapy (1)
-
MEC inhibitor (1)
-
Medalist trial (1)
-
medicaid (1)
-
Medicaid expansion (1)
-
medical burden (1)
-
Medical College of Wisconsin (1)
-
medical complications (2)
-
medical fellows (1)
-
medical fellowship (1)
-
medical oncologist (1)
-
medical oncology (1)
-
Medical Oncology Rosebank (1)
-
medical reporting (1)
-
Medical University of Vienna (2)
-
Medical University Vienna – Ge (1)
-
medicare (1)
-
medication adherence (1)
-
meditation (1)
-
medullary (1)
-
Meena Moran (1)
-
Meena S. Moran (2)
-
Meg Barbor (144)
-
Meg O'Brien (1)
-
Megan Caram (1)
-
Megan Daly (1)
-
Mehment Sitki Copur (1)
-
Melanie E. Royce (1)
-
Melanie Royce (2)
-
Melanie Seal (1)
-
melanoma (34)
-
Melanoma (2)
-
Melanoma Institute Australia (2)
-
melanoma survivor (1)
-
melflufen (1)
-
Melinda Bachini (1)
-
Melinda Telli (1)
-
Melissa Crouse (1)
-
Melissa Fryman (1)
-
Melissa Johnson (1)
-
Melissa McShane (1)
-
melphalan (1)
-
Memorial Sloan Kettering (78)
-
Memorial Sloan Kettering Cancer (2)
-
Memorial Sloan Kettering Cancer Center (26)
-
men (1)
-
meningioma (1)
-
menopausal symptoms (1)
-
menopause (2)
-
men's health (1)
-
mental health (2)
-
mental health status (1)
-
mental illness (1)
-
mentee (1)
-
mentor (2)
-
mentorship (3)
-
Meredith Baker (1)
-
merkel cell carcinoma (3)
-
Merrick I. Ross (1)
-
mesothelioma (3)
-
MET amplification (1)
-
MET mutation (2)
-
metabolic syndrome (3)
-
metastasectomy (2)
-
metastases (1)
-
metastasis (3)
-
metastasis free survival (1)
-
metastasis score (1)
-
metastatic (20)
-
metastatic bladder cancer (2)
-
metastatic breast cancer (20)
-
metastatic burden (1)
-
metastatic cancer (9)
-
metastatic cancer care (1)
-
metastatic cancer pain (1)
-
metastatic castration-resistant prostate cancer (1)
-
metastatic colon cancer (1)
-
metastatic colorectal cancer (9)
-
metastatic disease (3)
-
metastatic head and neck cancer (1)
-
metastatic hormone-naive prostat (1)
-
metastatic lung cancer (3)
-
metastatic melanoma (4)
-
metastatic nsclc (1)
-
metastatic prostate cancer (3)
-
metastatic renal cell carcinoma (1)
-
metastatic solid cancer (2)
-
metastatic solid tumors (1)
-
metastatic spinal cord compressi (1)
-
metastatic tumors (1)
-
metastatic urothelial cancer (1)
-
metastatic urothelial carcinoma (1)
-
METEOR trial (4)
-
metformin (2)
-
methotrexate (1)
-
methylation (1)
-
mFFOX (1)
-
mFOLFIRINOX (2)
-
mfolfox6 (2)
-
mFOLFOX6-bevacizumab (2)
-
Mhairi Copland (1)
-
mibc (2)
-
Michael Alvarado (1)
-
Michael Becker (3)
-
Michael Bookman (1)
-
Michael Cecchini (2)
-
Michael Davies (1)
-
Michael E. Williams (1)
-
Michael Feinstein (1)
-
Michael Fisch (1)
-
Michael Gnant (2)
-
Michael Green (1)
-
Michael Hoerger (1)
-
Michael Irwin (1)
-
Michael J. Hall (1)
-
Michael J. Overman (2)
-
Michael K. Gibson (1)
-
Michael Kraut (1)
-
Michael LeFevre (1)
-
Michael Link (1)
-
Michael Mauro (1)
-
Michael Overman (1)
-
Michael Perrotta (1)
-
Michael Pfreundschuh (2)
-
Michael Postow (3)
-
Michael Sabel (2)
-
Michael Schweizer (1)
-
Michael Stubblefield (1)
-
Michael T. Schweizer (1)
-
Michael Thompson (1)
-
Michael Van Scoy-Mosher (1)
-
Michael Wang (1)
-
Michel Ducreux (2)
-
Michela Casanova (1)
-
Michele Beau-Faller (1)
-
Michele Cavo (2)
-
Michele Schuman (1)
-
Michelle Dalton (1)
-
Michelle LeBeau (1)
-
Michelle Lynn Mierzwa (1)
-
microbes (1)
-
microbiota (1)
-
microsatellite instability (4)
-
microsatellite instability high (1)
-
microsatellite instability-high (1)
-
microsatellite stable (1)
-
middle income country (1)
-
middle-income country (1)
-
midgut (1)
-
midgut tumors (1)
-
midostaurin (1)
-
Miguel-Angel Perales (1)
-
Mike Armstrong (1)
-
Mikkael A. Sekeres (2)
-
Mikkael Sekeres (3)
-
MIKRAM KHARMACH (1)
-
Milan Anadkat (2)
-
Milena Sant (2)
-
Milind Javle (1)
-
Mindy Greenstein (2)
-
Mindy Tanzola (10)
-
Mingzhao Xing (1)
-
minimal residual disease (4)
-
minimally invasive (3)
-
minimally invasive surgery (1)
-
minority (1)
-
minority patients (1)
-
Mirat Shah (1)
-
Miri Ziv (2)
-
Miriam A. Knoll (1)
-
mirvetuximab soravtansine (1)
-
Mischa P. M. Nagel (1)
-
misdiagnosis (1)
-
mismatch repair (2)
-
mismatch repair deficiency (1)
-
mismatch repair-deficient (1)
-
mismatched repair genes (1)
-
missed appointments (1)
-
MIT (1)
-
Mitchell Cairo (2)
-
Mitchell Chan (1)
-
Mitchell Dowsett (2)
-
Mitchell Garrison (1)
-
Mitchell Smith (1)
-
Mithat Gonen (1)
-
mitomycin (1)
-
mitoxantrone (1)
-
MMed (1)
-
mmr (1)
-
mmr deficient (1)
-
MOAWIA MOHAMMED ALI ELHASSAN (1)
-
mobile app (1)
-
mobility (1)
-
modality therapy (1)
-
moderate-penetrance mutations (1)
-
Moffitt Cancer Care (1)
-
Moffitt Cancer Center (6)
-
MOHAMED ALORABI (1)
-
Mohammad Abu Zaid (1)
-
Mohammad K. Khan (2)
-
Mohammed Shimi (1)
-
molecular (1)
-
molecular analyses (1)
-
molecular analysis (3)
-
molecular biology (1)
-
molecular predictor (1)
-
molecular profiling (1)
-
molecular screening (2)
-
molecular subtypes (2)
-
molecular testing (2)
-
Molly MacDonald (1)
-
momelotinib (1)
-
monaleesa-7 (1)
-
MONARCH 2 (1)
-
Monash University (2)
-
Monica Bertagnolli (2)
-
Monica Morrow (2)
-
Monica Terenziani (1)
-
Monika Krzyzanowska (1)
-
Monique Hartley-Brown (1)
-
monoclonal antibodies (3)
-
monoclonal antibody (4)
-
monocytes (1)
-
monotherapy (5)
-
Montefiore Medical Center (2)
-
mood (1)
-
Moores Cancer Center (3)
-
MOR208 (1)
-
morbidity (1)
-
Morgan Romero (1)
-
mortality (3)
-
mortality rate (1)
-
Mothaffar Rimawi (1)
-
motolimod (1)
-
Mounika Addula (1)
-
Mount Sinai (2)
-
Mount Vernon Cancer Centre (1)
-
moxetumomab pasudotox (1)
-
MPH (1)
-
MPH; Jeff Summers (1)
-
mrcpc (1)
-
mrd (2)
-
MRI (3)
-
Mrinal Patnaik (2)
-
msi (1)
-
MSI mutation (1)
-
msi-h (1)
-
MSKCC (3)
-
MSLT2 trial (1)
-
mss (1)
-
Mt Sinai (1)
-
mTOR (1)
-
mTOR inhibitor (1)
-
mucositis (2)
-
Muhamad Alhaj Moustafa (1)
-
Muhamed Baljevic (1)
-
Muhammad Rafiqul Islam (2)
-
mulitcatheter brachytherapy (1)
-
multi fraction radiotherapy (1)
-
multicatheter interstitial brach (1)
-
multidisciplinary (3)
-
multidisciplinary care (1)
-
multidisciplinary health-care (1)
-
multikinase inhibitor (1)
-
multimodality (1)
-
multi-parametric (1)
-
multiple myeloma (55)
-
Multiple Myeloma (18)
-
MURANO (1)
-
MURANO trial (1)
-
MURIEL CUNNINGHAM (1)
-
Murray Brennan (5)
-
muscle (1)
-
muscle invasive (1)
-
muscle loss (1)
-
muscle mass (1)
-
muscle strength (1)
-
muscle-invasive (1)
-
muscle-invasive bladder cancer (5)
-
musculoskeletal symptom (1)
-
mutated pathways (1)
-
mutation burden (2)
-
mutations (2)
-
MYC (1)
-
MYC translocation (1)
-
mycophenolate mofetil (1)
-
myeloablative AHCT (1)
-
Myelodysplastic Syndomes (3)
-
myelodysplastic syndrome (9)
-
myelofibrosis (6)
-
myeloid growth factors (1)
-
myeloid neoplasms (1)
-
myeloma (8)
-
myeloma clones (1)
-
myeloproliferative neoplasms (2)
-
Myl-1401O. (1)
-
MyPathway trial (1)
-
N. Lynn Henry (1)
-
Nabiel Mir (1)
-
nab-paclitaxel (9)
-
NADA SULIMAN HAJ MUKHTAR (1)
-
Nadeem Abu-Rustum (1)
-
Nadia Harbeck (1)
-
Nadine Tung (1)
-
Nafisa Abdelhafiez (1)
-
Nagashree Seetharamu (2)
-
NAGI EL SAGHIR (1)
-
NAGI S. EL SAGHIR (1)
-
Nagi S. El-Saghir (2)
-
naive T cell depletion (1)
-
Naiyer Rizvi (2)
-
nala trial (2)
-
Namrata Vijayvergia (1)
-
Nancy Davidson (4)
-
Nancy Lin (3)
-
Nantes University Hospital (2)
-
Narjust Duma (1)
-
Narjust Florez (Duma) (1)
-
Narmin Talibova (1)
-
Natasha Leighl (1)
-
Natasha Stout (1)
-
Nathalie McKenzie (2)
-
Nathan Fowler (2)
-
Nathan Hale Fowler (1)
-
Nathan Pennell (1)
-
National Cancer Center Bejing (1)
-
National Cancer Center Hospital (1)
-
National Cancer Data Base (1)
-
National Cancer Database (2)
-
National Cancer Institute (14)
-
National Cancer Institute of Mil (1)
-
National Coalition for Cancer Research (1)
-
National Jewish Health (1)
-
national policy (1)
-
National Taiwan University (1)
-
natural killer cells (2)
-
nausea (6)
-
Naveen Pemmaraju (1)
-
Navneet Majhail (2)
-
Nawfel Mellas (1)
-
NCCN (64)
-
nccn 2020 (5)
-
NCCN 22nd Annual Conference (4)
-
nccn annual conference (6)
-
NCCN guidelines (11)
-
NCCN Hematologic Malignancies (19)
-
nccn, nccn annual conference, 4R model, pathways (1)
-
NCCTG N063H (1)
-
NCI (6)
-
NCI cancer center (2)
-
NCTN (1)
-
Neal Chawla (1)
-
Neal Meropol (3)
-
Neal Ready (1)
-
Neal Shore (1)
-
Nebraska Cancer Specialists (1)
-
Nebraska Medicine (1)
-
necitumumab (2)
-
neck dissection (1)
-
needle biopsy (1)
-
Neel U. Sukhatme (1)
-
Neeraj Agarwal (2)
-
Neil Canavan (4)
-
Neil Iyengar (2)
-
Neil Vasan (1)
-
NEJ026 trial (1)
-
nelipepimut-s (1)
-
Nelli Benjanyan (1)
-
Nelson Peralta (1)
-
Nengliang Yao (1)
-
neoadjuvant (3)
-
neoadjuvant chemotherapy (9)
-
neoadjuvant ipilimumab (2)
-
neoadjuvant radiation (1)
-
neoadjuvant therapy (8)
-
neoadjuvant treatment (6)
-
neoantigen (1)
-
neoantigen vaccine (1)
-
neoMONARCH (1)
-
neoMONARCH trial (1)
-
NEOSCOPE trial (1)
-
NeoSphere trial (1)
-
neotrip (1)
-
nephrectomy (8)
-
neratinib (3)
-
Netherlands Cancer Institute (5)
-
Netherlands Comprehensive Cancer (1)
-
NETs (1)
-
NETTER-1 (1)
-
NETTER-1 trial (1)
-
neuroblastoma (5)
-
neurocognitive (1)
-
neuroendocrine (1)
-
neuroendocrine disease (1)
-
neuroendocrine tumors (7)
-
neurologic side effects (1)
-
neurologic toxicity (1)
-
neuropathic pain (2)
-
neuropathy (5)
-
neurotoxicity (4)
-
neutropenia (3)
-
never smoker (1)
-
never smokers (2)
-
new mexico (1)
-
New York University (1)
-
newly diagnosed cancer patients (1)
-
NewYork-Presbyterian (1)
-
next generation sequencing (1)
-
next therapy (1)
-
next-generation sequencing (3)
-
nf1 (1)
-
NGS (6)
-
NHL (6)
-
Nicholas J. Vogelzang (1)
-
Nicholas James (5)
-
Nicholas Simon (1)
-
Nicholas Turner (5)
-
Nicolaus Kröger (1)
-
Nicole Kuderer (1)
-
Nicole Mittmann (1)
-
Nicole Shonka (1)
-
Nicolò Matteo Luca Battisti (1)
-
nicotinamide (2)
-
Nienke A. de Glas (1)
-
Nikhil Wagle (2)
-
nilotinib (2)
-
Nina Rosa Neuendorff (1)
-
Nina Shah (1)
-
nintedanib (1)
-
niraparib (8)
-
Nirupa Raghunathan (5)
-
Nita Ahuja (1)
-
Nithya Krishnan (2)
-
Nitin Jain (1)
-
Nitin Mehrotra (1)
-
nivolumab (49)
-
nivolumab dosing (1)
-
nivolumab monotherapy (3)
-
NIVOREN GETUG-AFU 26 (1)
-
NIZAR TANNIR (1)
-
nk cells (1)
-
NK1 inhibitor (1)
-
nodal irradiation (1)
-
nodal radiation (1)
-
nodal response (1)
-
node negative (1)
-
node-negative (5)
-
node-positive (2)
-
node-positive disease (1)
-
nodules (2)
-
Noelle LoConte (1)
-
non-bulky (1)
-
non-clear cell renal cancer (2)
-
noncolorectal GI cancers (1)
-
non-favorable AML (1)
-
Non-Hodgkin lymphoma (12)
-
nonmelanoma skin cancer (2)
-
non-melanoma skin care (2)
-
nonmetastatic (2)
-
non-muscle invasive (1)
-
non-muscle-invasive bladder canc (1)
-
nonpharmacological techniques (1)
-
nonseminoma (1)
-
non-small cell lung cancer (33)
-
non–small cell lung cancer (4)
-
nonsmoking-associated (1)
-
non-specific symptoms (1)
-
nonsquamous (3)
-
nonverbal (1)
-
Nora Janjan (2)
-
Nordwest Hospital (2)
-
NORMAN J. LACAYO (1)
-
Norman Sharpless (3)
-
Norman Wolmark (2)
-
Norris Cotton Cancer Center (1)
-
North Shore LIJ (1)
-
NorthShore University Health (1)
-
Northwestern (1)
-
Northwestern University (5)
-
novel agents (1)
-
novel combination (1)
-
novel drug targets (1)
-
novel pathways (1)
-
novel-novel (1)
-
n-Pacific Lymphoma 2016 (1)
-
NRG Oncology (6)
-
NRG Oncology/NSABP B-42 (2)
-
NRG Oncology/NSABP B-42 trial (1)
-
NRG Oncology/NSABP B-52 trial (1)
-
nrg/nsabp (1)
-
NRG/RTOG 0712 (1)
-
NSABB (1)
-
NSABP (2)
-
NSABP 35 (1)
-
NSABP B20 (1)
-
NSABP B-35 (1)
-
NSABP B-36 (1)
-
NSABP B-47 trial (1)
-
NSABP clinical trials (1)
-
NSCLC (69)
-
NSGO-PALEO / ENGOT-EN3 trial (1)
-
nursing homes coronavirus (1)
-
nut consumption (1)
-
NYU (2)
-
NYU Langone (2)
-
NYU Perlmutter Cancer Center (2)
-
OAK trial (2)
-
obamacare (1)
-
obesity (5)
-
obinutuzumab (11)
-
objective response (1)
-
observation (3)
-
OCE members (1)
-
Octreotate (1)
-
Octreotide (1)
-
Ogidiagba Louis Efe (1)
-
ogliometastatic (1)
-
ogliometastatic disease (1)
-
Ohio State University (3)
-
OhioHealth (2)
-
Ohiohealth Kobacker House (1)
-
Ola Landgren (3)
-
olanzapine (3)
-
olaparib (12)
-
olaratumab (1)
-
older cancer survivor (1)
-
older patients (11)
-
oligometastatic (5)
-
Oliver Sartor (4)
-
Olivier Casasnovas (4)
-
Olivier Chinot (1)
-
Olivier Tredan (1)
-
Ollie Minton (1)
-
Olufunmilayo I. Olopade (2)
-
OlympiAD trial (1)
-
omega-3 fatty acid (1)
-
Omid Hamid (2)
-
omitting surgery (1)
-
oncologic surgery (1)
-
oncologist partnering (1)
-
oncologist perception (1)
-
oncology (53)
-
oncology care (1)
-
Oncology Care Model (2)
-
oncology in India (1)
-
oncology in South America (1)
-
oncology in the Middle East (1)
-
oncology provider (1)
-
OncologyGo (4)
-
oncopolicy (1)
-
Oncotype DX (5)
-
online curriculum (1)
-
online patient information (1)
-
online tumor board (1)
-
oocyte (1)
-
OP-106 Horizon (1)
-
OpACIN trial (2)
-
open (1)
-
open resection (1)
-
open transthoracic (1)
-
operable cancer (1)
-
opiates (1)
-
opinion (4)
-
opiod prescribing (1)
-
opiod risk (1)
-
opioid (3)
-
opioid abuse (1)
-
opioid access (2)
-
opioid addiction (1)
-
opioid epidemic (1)
-
opioid reduction (1)
-
opioid use (1)
-
opioid use disorder (1)
-
opioid-associated death (1)
-
opioids (6)
-
opioids and cancer pain (1)
-
opportunity cost (1)
-
optimal sequencing (1)
-
OPTIMAL>60 study (1)
-
oral anticoagulants (2)
-
oral azacitidine (1)
-
oral cancer (1)
-
oral cavity (1)
-
oral chemotherapy (1)
-
oral HPV infection (1)
-
oral mucositis (1)
-
oral paclitaxel (1)
-
oral regimen (1)
-
Oregon (1)
-
Oregon Health & Science (1)
-
Oregon Health & Science Universi (1)
-
organ preservation (1)
-
oriole trial (1)
-
oropharyngeal (1)
-
oropharyngeal cancer (4)
-
Oscar B. Goodman (1)
-
OSCAR GUEVARA (1)
-
osimertinib (2)
-
osteoradionecrosis (1)
-
OSUCCC (1)
-
other-cause mortality (1)
-
Otis Brawley (1)
-
Ottawa Hospital Cancer Centre (1)
-
Otterson (1)
-
OUISSAM AL JARROUDI (1)
-
outcome (1)
-
outcomes (2)
-
outcomes analysis (1)
-
outcomes research (1)
-
out-of-pocket costs (1)
-
outpatient care (1)
-
outpatient treatment (1)
-
ovarian cancer (25)
-
ovarian failure (1)
-
ovarian function (2)
-
ovarian function suppression (2)
-
ovarian insufficiency (1)
-
ovarian suppression (7)
-
overall survival (22)
-
overall survival analysis (2)
-
overtreatment (2)
-
OVHIPEC trial (1)
-
Owen N. Witte (1)
-
Owen O'Connor (1)
-
oxaliplatin (13)
-
Oxford University (1)
-
oxybutynin (1)
-
oxygen (1)
-
p16 (1)
-
PAC (1)
-
pace-b trial (1)
-
PACIFIC trial (3)
-
paclitaxel (19)
-
pacritinib (1)
-
PADMA trial (1)
-
Padmanee Sharma (1)
-
pain (2)
-
pain assessment (2)
-
pain flare (1)
-
pain management (4)
-
Pain Management (2)
-
pain relief (2)
-
pain score (1)
-
painful bone metastases (1)
-
painkillers (1)
-
PAKT trial (1)
-
palb2 (1)
-
palbociclib (11)
-
PALLAS trial (1)
-
palliative (1)
-
palliative care (33)
-
Palliative Care (2)
-
palliative care clinicians (2)
-
palliative care in cancer (1)
-
palliative care integration (1)
-
palliative chemotherapy (1)
-
PALOMA (1)
-
PALOMA 3 (1)
-
PALOMA-1/TRIO 18 (1)
-
PALOMA3 (2)
-
palpable stage 3 melanoma (2)
-
Pam Kohl (1)
-
Pamela Kunz (1)
-
PAMELA trial (2)
-
Pan Pacific Lymphoma (16)
-
PANACEA (1)
-
pancreatic cancer (25)
-
Pancreatic Cancer (11)
-
pancreatic carcinoma (1)
-
pancreatic ductal adenocarcinoma (1)
-
pancreatic ductal carcinoma (1)
-
pancreatic resection (1)
-
pancreatic tumors (1)
-
pandemic (1)
-
panitumumab (1)
-
PANKAJ JANI (1)
-
panobinostat (1)
-
Pan-Pacific Lymphoma 2016 (17)
-
Paola Gaggiotti (1)
-
paola-1 (1)
-
paola-1/engot-ov25 trial (1)
-
Paoli Palmettes Institute (2)
-
Paolo Ascierto (2)
-
Paolo Strati (1)
-
papillary RCC (1)
-
papillary renal cell carcinoma (2)
-
Parameswaran Hari (3)
-
parents (1)
-
Parkland Health System (1)
-
Parminder Singh (1)
-
PARP inhibitor (9)
-
PARP inhibitors (4)
-
partial breast radiation (2)
-
partial breast re-irradiation (1)
-
partial-breast irradiation (1)
-
partnership (1)
-
Parvez Dara (4)
-
Pasi Jänne (2)
-
Pasi S. Jänne (2)
-
passenger mutations (1)
-
pathologic (1)
-
pathologic complete response (4)
-
pathology (1)
-
pathway (1)
-
pathways (5)
-
Pati Schembari (1)
-
patient advocacy (1)
-
patient advocate (3)
-
patient burden (1)
-
patient care (1)
-
patient communication (1)
-
patient costs (1)
-
patient counseling (1)
-
patient decision-making (1)
-
patient distress (1)
-
patient education (1)
-
patient engagement (1)
-
patient experience (1)
-
patient features (1)
-
patient feedback (1)
-
patient information (1)
-
patient navigation (2)
-
patient navigator (1)
-
patient outcomes (3)
-
patient perception (1)
-
patient perspective (1)
-
patient preference (2)
-
patient reported outcomes (3)
-
patient reporting (1)
-
patient safety (1)
-
patient satisfaction (1)
-
patient selection (2)
-
patient-centered cancer care (1)
-
patient-centered care (5)
-
patient-reported data (1)
-
patient-reported outcome (2)
-
patient-reported outcomes (7)
-
patient-reported surveys (1)
-
patient-reported symptoms (1)
-
patients (1)
-
Patricia Eifel (1)
-
Patricia Ganz (9)
-
Patricia Hurley (1)
-
Patricia J. Goldsmith (1)
-
PATRICIA trial (1)
-
Patrick Beauregard (2)
-
Patrick Boland (1)
-
Patrick Eck (1)
-
Patrick Forde (1)
-
Patrick M. Lynch (1)
-
Patrick Schoffski (1)
-
Patrick Schöffski (1)
-
patterns of care (1)
-
Paul A. Bunn Jr (3)
-
Paul Bunn (4)
-
Paul Chapman (1)
-
Paul Goss (1)
-
Paul Jacobsen (2)
-
Paul Kalanithi (2)
-
Paul Kluetz (2)
-
Paul M. Cinciripini (1)
-
Paul Nguyen (7)
-
Paul O'Gorman Leukaemia Research (1)
-
Paul Richardson (4)
-
Paul Weiden (1)
-
Pauline Funchain (1)
-
PAVLOS MSAOUEL (1)
-
payer (1)
-
payer perspective (1)
-
Paz-Ares (1)
-
pazopanib (5)
-
pbi (1)
-
PCORI (1)
-
PCP (1)
-
PCR (4)
-
PD-1 (3)
-
pd-1 blockade (4)
-
PD-1 combination therapy (1)
-
PD-1 inhibitors (2)
-
PD-1 monotherapy (1)
-
PD-1 therapy (1)
-
PD1-blockers (1)
-
PDAC (2)
-
PDC (1)
-
PDL1 (3)
-
PD-L1 (16)
-
PD-L1 immunotherapy (1)
-
PD-L1 inhibition (1)
-
PD-L1 positive (1)
-
PDL1 staining (1)
-
PDL1-blockers (1)
-
pd-l1-negative (1)
-
PD-L1-positive (2)
-
PDL2 expression (1)
-
pearl trial (1)
-
pediatric (2)
-
pediatric cancer (3)
-
pediatric chemotherapy (1)
-
pediatric leukemia (2)
-
pediatric oncology (3)
-
Pedram Razavi (1)
-
pegilodecakin (1)
-
pegph20 (1)
-
pelvic lymph node (1)
-
pelvic radiation (1)
-
pembrolizumab (48)
-
pemetrexate (1)
-
pemetrexed (3)
-
penile cancer (2)
-
Pennsylvania Hematology Oncology (1)
-
Pennsylvania Hospital (2)
-
peptide-paclitaxel conjugate (1)
-
peptides (1)
-
Pere Gascón (1)
-
performance measures (1)
-
perimenopausal (1)
-
periodontal disease (1)
-
perioperative (1)
-
perioperative chemotherapy (1)
-
peripheral blood stem cell (1)
-
peripheral blood stem cells (1)
-
peripheral neuropathy (1)
-
peripheral T cell lymphoma (3)
-
peripheral T-cell lymphoma (2)
-
peritoneal cancer (1)
-
peritoneal carcinoma (2)
-
peritoneal carcinomatosis (2)
-
peritoneal metastases (1)
-
Persephone trial (2)
-
PERSIST Trial (2)
-
personal doses (1)
-
personalized cancer care (1)
-
personalized medicine (6)
-
personalized treatment (2)
-
personalized vaccine (1)
-
pertuzumab (5)
-
PET (3)
-
PET CT (1)
-
PET scan (7)
-
Peter Bach (3)
-
Peter Clark (2)
-
Peter Greenberg (1)
-
Peter Hoskin (1)
-
Peter Johnstone (1)
-
Peter L.J. Naredi (1)
-
Peter MacCallum Cancer Centre (4)
-
Peter MacCallum Centre (3)
-
Peter Naredi (1)
-
Peter O'Donnell (1)
-
Peter Paul Yu (4)
-
Peter Shields (2)
-
Peter Watson (1)
-
Peter Yu (1)
-
Peter Wiernik (1)
-
Petros Grivas (1)
-
pfs (6)
-
Ph+ ALL (1)
-
phaedra trial (1)
-
PHARE trial (1)
-
pharmacogenomic (1)
-
phase 1 trials (1)
-
phase I clinical trial (1)
-
phase I trial (1)
-
PhD (2)
-
PhD; and Olexiy Kovalyov (1)
-
PhD; Iryna Kriachok (1)
-
PhD; Ivan Smolanka (1)
-
PhD; Jennifer J. Gao (1)
-
PhD; LAWRENCE N. SHULMAN (1)
-
PhD; Nataliia Dovganych (1)
-
PHIL FALKOWITZ (1)
-
philadelphia chromosome (1)
-
Philip A. Thompson (2)
-
Philip Bonomi (5)
-
Philip Champion (1)
-
Philip Kantoff (2)
-
Philip Salem (1)
-
Philip Stella (1)
-
Philippe Rochigneux (2)
-
Philippe Spiess (1)
-
Phillip Gray (1)
-
Ph-negative (1)
-
photon therapy (1)
-
physical activity (2)
-
physical experience (1)
-
physical function (1)
-
physical therapy (1)
-
physician burnout (1)
-
physician’s choice (1)
-
physician-assisted death (1)
-
physician-assisted suicide (1)
-
physician-led (1)
-
Physicians' Health Study (1)
-
PI3K (2)
-
PI3K inhibition (1)
-
PI3K inhibitor (2)
-
pictilisib (2)
-
PIK3CA (2)
-
Piyush Agarwal (1)
-
placebo effect (1)
-
PlanB trial (1)
-
plasma (1)
-
plasma cell leukemia (1)
-
plasma cell-free DNA (1)
-
plasma DNA (1)
-
plasmacytoma (1)
-
plasmamatch (1)
-
platelet transfusion (1)
-
platinum (1)
-
platinum chemotherapy (7)
-
platinum combination chemotherap (1)
-
platinum-based (1)
-
platinum-based chemo (1)
-
platinum-based chemotherapy (2)
-
platinum-ineligible (2)
-
platinum-resistant (2)
-
platinum-sensitive (4)
-
playwright (1)
-
PLD-1 (1)
-
plenary (1)
-
pneumonitis (2)
-
polatuzumab vedotin (2)
-
policy (3)
-
policy issues (2)
-
politics (2)
-
polo trial (1)
-
polybromo (1)
-
polycythemia vera (1)
-
polygenic risk scores (1)
-
polymerase epsilon mutation (1)
-
pomalidomide (2)
-
ponatinib (2)
-
Ponnandai S. Somasundar (1)
-
pooled data analysis (1)
-
poor prognosis (2)
-
poor response (1)
-
poor-prognosis (2)
-
poor-prognosis tumors (1)
-
poor-risk (1)
-
POSH study (1)
-
positive lymph nodes (2)
-
positron emission tomography (1)
-
positron emission topography (2)
-
postmenopausal (10)
-
postmenopausal breast cancer (4)
-
postmenopausal patients (1)
-
postmenopausal women (1)
-
postoperative radiation (2)
-
postplatinum (1)
-
post-remission (1)
-
postsurgery (1)
-
postsurgical (1)
-
postsurgical syndromes (1)
-
post-treatment care (1)
-
post-treatment services (1)
-
Prasad Adusumilli (1)
-
Prashant Kapoor (1)
-
precision medicine (7)
-
precision oncology (1)
-
predict survival (1)
-
predictive biomarker (2)
-
predictive biomarkers (1)
-
predictive factors (1)
-
prednisone (9)
-
Preety Narayan (1)
-
pregnancy (5)
-
premenopausal (6)
-
pre-menopausal (1)
-
premenopausal breast cancer (1)
-
premenopausal patients (1)
-
premenopausal women (1)
-
PREOPANC-1 (1)
-
preoperative (1)
-
preoperative chemotherapy (1)
-
preoperative exercise (1)
-
preoperative radiotherapy (1)
-
prescribing opioids (1)
-
presurgery (2)
-
pretreated (3)
-
pretreated colorectal cancer (1)
-
prevention (1)
-
previously treated lung cancer (1)
-
prexasertib (1)
-
PRIMA trial (1)
-
prima/engot-ov26/gog-3012 (2)
-
primary care (2)
-
primary care physician (1)
-
primary care provider (2)
-
primary glioma (1)
-
primary treatment (1)
-
primary tumor location (1)
-
primary tumors (1)
-
Primo Lara (1)
-
Princess Dina Mired (1)
-
Princess Margaret Cancer Centre (4)
-
Princess Margaret Hospital (5)
-
prior authorization (1)
-
Priscilla Brastianos (3)
-
procarbazine (1)
-
PRODIGE 24 (1)
-
PRODIGE 7 (1)
-
PRODIGY 12-ACCORD 18 (3)
-
Prof. Kouhen Fadila (1)
-
ProfilER study (1)
-
profound trial (1)
-
progestin (1)
-
prognosis (2)
-
prognostic (2)
-
prognostic awareness (1)
-
prognostic biomarker (2)
-
prognostic information (1)
-
prognostic model (1)
-
prognostic models (1)
-
prognostic stage (1)
-
prognostic uncertainty (1)
-
prognostication (1)
-
programmed cell death ligand 1 (1)
-
programmed cell death protein 1 (1)
-
progress (2)
-
progression-free survival (9)
-
progressive cancer (1)
-
project facilitate (1)
-
prolonged grief disorder (1)
-
PROMIS (1)
-
PROMIS group (1)
-
PROMISE trial (1)
-
proof of concept (1)
-
pros (3)
-
pros and cons (1)
-
PROSPER trial (2)
-
prostate (1)
-
prostate bed (1)
-
prostate cancer (98)
-
Prostate Cancer (26)
-
prostate cancer guidelines (1)
-
prostate cancer subclass (1)
-
prostate specific antigen (1)
-
prostatectomy (4)
-
prostate-specific antigen (3)
-
ProtecT (1)
-
PROTECT trial (1)
-
PRO-TECT trial (1)
-
proton beam radiotherapy (2)
-
proton therapy (3)
-
provider roles (1)
-
prudence francis (2)
-
PSA (5)
-
psychiatry and cancer (1)
-
psychological (1)
-
psychological experience (1)
-
psychological intervention (1)
-
psychological support (1)
-
psycho-oncology (1)
-
psychosocial (3)
-
psychosocial care (3)
-
psychosocial distress screening (1)
-
psychosocial services (1)
-
PTCL (3)
-
public health (1)
-
pyramid trial (1)
-
Qian Shi (1)
-
QMAP (1)
-
qol (5)
-
QTP (1)
-
QUADRA (1)
-
quadruplet (1)
-
quality (1)
-
quality assessment (1)
-
quality cancer care (2)
-
quality care (20)
-
quality care in cancer (1)
-
quality control (1)
-
quality improvement (3)
-
quality in cancer care (2)
-
quality measurement (1)
-
quality measures (1)
-
quality of care (3)
-
quality of life (33)
-
quality of life survivor (1)
-
quality reporting (1)
-
quality training (1)
-
quality-adjusted survival (1)
-
quazar trial (1)
-
Queen Elizabeth Hospital (1)
-
Queen Mary University of London (5)
-
quitting smoking (1)
-
Quyen Chu (2)
-
R. Angelo de Claro (2)
-
R. GREGORY BOCIEK (1)
-
Raamis Khwaja (1)
-
Rabin Medical Center (2)
-
race (2)
-
Rachel Freedman (1)
-
Rachel Grisham (1)
-
Rachel Joseph (1)
-
Rachel Lynn Yung (2)
-
Rachel Tompa (1)
-
Rachelle Bernacki (2)
-
racial disparities (2)
-
racial disparity (1)
-
RAD001 (1)
-
Radhakrishna Vemuri, Jo Cavallo (1)
-
RADIANT-4 (1)
-
radiation (10)
-
radiation boost (1)
-
radiation dose (1)
-
radiation fractionation (2)
-
radiation oncology (6)
-
radiation oncology service (1)
-
radiation therapy (14)
-
radical cystectomy (1)
-
radical prostatectomy (4)
-
radioactive iodine (1)
-
radioembolization (1)
-
radiographic pfs (1)
-
radioimmunotherapy (2)
-
radiology (1)
-
radiosurgery (2)
-
radiotherapeutic sensitivity (1)
-
radiotherapy (37)
-
radiotherapy deintensification (1)
-
radiotherapy delivery (1)
-
radiotherapy dose (1)
-
radiotherapy oral complications (1)
-
radiotherapy safety (1)
-
radium (1)
-
Radium 223 (1)
-
RADPAC trial (1)
-
Rafal Dziadziuszko (1)
-
Rafat Abonour (2)
-
RAINFALL trial (1)
-
Rajiv Pruthi (1)
-
Rajiv Shah (1)
-
Rakesh Chopra (5)
-
Ralph Hauke (2)
-
Ramaswamy Govindan (4)
-
Ramesh Ramanathan (1)
-
RAMI MANOCHAKIAN (1)
-
Ramu Kandasamy (1)
-
ramucirumab (4)
-
Rana McKay (7)
-
Randall Holcombe (1)
-
Randi Gould (3)
-
Randy Sweis (1)
-
Randy Wei (1)
-
range trial (1)
-
Ranjana Advani (1)
-
RANK lignad inhibitors (1)
-
Raphael E. Pollock (1)
-
rare cancers (1)
-
rare mutations (1)
-
rare tumors (2)
-
RARG coding variant (1)
-
RAS (2)
-
RAS wild type (1)
-
Rashmi Chugh (1)
-
RAS-mutation (1)
-
RATIFY trial (1)
-
RAVI AMARAVADI (1)
-
Ravi Mehrotra (2)
-
Ravindran Kanesvaran (1)
-
Rawad Elias (2)
-
Ray Page (1)
-
rbc (1)
-
RCC (25)
-
R-CHOP (7)
-
R-CHP (1)
-
REBECCA GLOMMEN (1)
-
Rebecca Johnson (2)
-
Rebecca Karp Leaf (1)
-
Rebecca Roy Thomas (1)
-
Rebecca Saracino (1)
-
RECORD 1 Trial (1)
-
record encounters (1)
-
rectal cancer (8)
-
rectal toxicity (1)
-
recurrence (6)
-
recurrence score (1)
-
recurrent cancer (2)
-
recurrent disease (1)
-
recurrent glioma (1)
-
recurrent head and neck cancer (1)
-
recurrent ovarian cancer (2)
-
red blood cell transfusion (2)
-
reduced high-dose volume radioth (1)
-
reduced intensity (2)
-
reducing opioid use (1)
-
reducing opioids (1)
-
reduse trial (1)
-
Reena A. George (1)
-
reflect study (1)
-
refractory (15)
-
refractory disease (6)
-
refractory Hodgkin lymphoma (1)
-
refractory mm (1)
-
refractory multiple myeloma (2)
-
Regine Nshimiyimana Maniraho (2)
-
regression-free survival (1)
-
rehabilitation (1)
-
reimbursement (2)
-
relapsed (12)
-
relapsed cancer (2)
-
relapsed disease (4)
-
relapsed mm (1)
-
relapsed multiple myeloma (2)
-
relapsed PTCL (1)
-
relapsed/refractory (2)
-
relapsed/refractory disease (2)
-
relaxation (1)
-
relay trial (1)
-
RELEVANCE trial (1)
-
remission (3)
-
Rena Conti (1)
-
renal cancer (4)
-
renal cell (1)
-
renal cell carcinoma (51)
-
Renata Urban (1)
-
RENEE MARIA SALIBY (1)
-
research (1)
-
research infrastructure (1)
-
resectable (2)
-
resectable cancer (2)
-
resectable gastric cancer (1)
-
resectable pancreatic cancer (1)
-
resected disease (1)
-
resected non small cell lung can (1)
-
resection (5)
-
Reshma Jagsi (2)
-
residual disease (2)
-
residual distant recurrence (1)
-
residual invasive disease (1)
-
resilience (2)
-
resistance mechanisms (2)
-
resistance pathways (1)
-
RESONATE-2 trial (1)
-
resource availability (1)
-
resources (1)
-
respiratory distress (1)
-
response rate (1)
-
response to treatment (1)
-
response-adapted chemotherapy (1)
-
restrictive prescribing (1)
-
ret fusion (1)
-
ret inhibitor (1)
-
retrospective (1)
-
Reverend Tawana Davis (1)
-
rhabdoid (1)
-
rhabdoid rcc (1)
-
rhabdomyosarcoma (1)
-
ribociclib (1)
-
Rich Rubenstein (1)
-
Richard A. Berjian (1)
-
Richard Ablin (2)
-
Richard Boxer (3)
-
Richard Brodkin (1)
-
Richard Cassidy (1)
-
Richard Champlin (1)
-
Richard E. Harris (1)
-
Richard Finn (4)
-
Richard Fisher (4)
-
Richard G. Abramson (1)
-
Richard Goldberg (3)
-
Richard Grenell (1)
-
Richard Herrmann (1)
-
Richard Hite (1)
-
Richard Hoppe (1)
-
Richard J. Boxer (18)
-
Richard L. Schilsky (1)
-
Richard Lee (1)
-
Richard Levine (1)
-
Richard M. Boulay (2)
-
Richard M. Stone (5)
-
Richard Margolese (4)
-
Richard Pazdur (9)
-
Richard S. Finn (1)
-
Richard Schilsky (7)
-
Richard Stone (9)
-
right side tumor (1)
-
right to try (2)
-
rigosertib (1)
-
Rigshospitalet (1)
-
Rimas Lukas (5)
-
Rinaa Punglia (1)
-
ring sideroblasts (1)
-
Rishi Surana (2)
-
rising costs (1)
-
risk assessment (1)
-
risk of death (2)
-
risk score (1)
-
risk status (1)
-
risk stratification (3)
-
rituximab (27)
-
rituximab follicular lymphoma (1)
-
rituximab maintenance (2)
-
rituximab-refractory (1)
-
rivaroxaban (1)
-
roar trial (1)
-
Robert A. Swarm (1)
-
Robert Bonney (1)
-
Robert Carlson (6)
-
Robert Chapman (1)
-
Robert Coleman (2)
-
Robert Croyle (2)
-
Robert Figlin (2)
-
Robert H. Lurie (3)
-
Robert Haddad (1)
-
Robert Harrison (1)
-
Robert J. Green (1)
-
Robert J. Jones (1)
-
Robert Kuske (2)
-
Robert L. Coleman (2)
-
Robert Livingston (1)
-
Robert Manges (1)
-
Robert Marcus (1)
-
Robert Miller (3)
-
Robert Motzer (2)
-
Robert Peter Gale (19)
-
Robert Rifkin (2)
-
Roberto Leon-Ferre (1)
-
Roberto Luksch (1)
-
Robin Hardbattle (1)
-
Robin Zon (1)
-
robot-assisted surgery (1)
-
robotic (1)
-
rocapuldencel-T (1)
-
Roger G. Lawrence (1)
-
Roger Henriksson (1)
-
Roger Rawlings (1)
-
Rogerio Lilenbaum (1)
-
Roisin Connolly (1)
-
Roland Seiler (2)
-
rolapitant (1)
-
role function (1)
-
Rolf Stahel (2)
-
Romain Cohen (1)
-
Romana (2)
-
Romano 1 (1)
-
Romano 2 (1)
-
romidepsin (1)
-
Ronald A. DePinho (8)
-
Ronald Blum (1)
-
Ronald Buckanovich (2)
-
Ronald Chen (3)
-
Ronald DePinho (1)
-
Ronald E. Turk (1)
-
Ronald Go (2)
-
Ronald Hoffman (1)
-
Ronald Maggiore (1)
-
Ronald Piana (880)
-
Ronit Leiba (1)
-
Rosa Nouvini (1)
-
Roswell Park (2)
-
rovalpituzumab tesirine (1)
-
Rova-T (3)
-
Rowan Chlebowski (4)
-
Roy Decker (2)
-
Roy Herbst (7)
-
Roy S. Herbst (1)
-
Royal Brompton Hospital (1)
-
Royal Marsden (1)
-
Royal Marsden Hospital (5)
-
Royal Marsden Hospital NHS Trust (1)
-
Royal Marsden NHS Foundation Tru (1)
-
Royal Marsden NHS Foundation Trust (1)
-
Rozalina G McCoy (1)
-
rpfs (1)
-
rt (1)
-
RTOG (3)
-
RTOG 0415 (4)
-
RTOG 0539 (1)
-
RTOG 0617 (2)
-
RTOG 9601 (3)
-
RTOG trial (1)
-
RTOG0521 (1)
-
Ruben A. Mesa (1)
-
Ruben Mesa (11)
-
rucaparib (2)
-
Rudiger Hehlmann (1)
-
Rujuta Saksena (2)
-
rural cancer care (1)
-
rural health care (2)
-
Rush Medical College (2)
-
Rush University Medical Center (3)
-
Rustam Tursun-Zade (1)
-
Rutgers Cancer Institute (2)
-
Rutgers University (1)
-
Ruth Etzioni (1)
-
Ruth Mary Parks (1)
-
Ruth O’Regan (1)
-
Ruth O'Regan (8)
-
ruxolitinib (1)
-
Rwanda (1)
-
Ryan Nguyen (1)
-
Ryan Rodriguez (1)
-
S. MONICA SONI (4)
-
S. Vincent Rajkumar (11)
-
s-1 (3)
-
Saad Usmani (6)
-
Saad Z. Usmani (1)
-
SABCS (2)
-
SABCS 2015 (31)
-
SABCS 205 (1)
-
Saber Boutayeb (1)
-
Sabin Russell (1)
-
Sabine Linn (1)
-
Sabine Siesling (2)
-
sabr (2)
-
SABR-COMET (2)
-
sacituzumab govitecan (2)
-
Safa El Kefi (1)
-
safe opiod disposal (1)
-
safe opiod storage (1)
-
safety (1)
-
safety in cancer care (1)
-
safety incidents (1)
-
Sagar Lonial (24)
-
SAID AFQIR (1)
-
Saitama Medical University International Medical Center (1)
-
Salah Osman (1)
-
Salah-Eddin Al-Batran (3)
-
salivary gland (1)
-
salivary glands (1)
-
Sally Luckett (1)
-
salvage management (1)
-
salvage radiation (1)
-
salvage radiation therapy (2)
-
salvage radiotherapy (2)
-
salvage therapy (1)
-
salvage treatment (1)
-
Sam Silver (3)
-
Sameer Mahesh (1)
-
Samer Khaled (1)
-
Samlau Kutana (1)
-
Samuel A. Kareff (1)
-
Samuel Chao (2)
-
Samuel Oschin Comprehensive Canc (1)
-
Samuel Rosner (1)
-
Samuel Rubinstein (1)
-
Samuel Silver (3)
-
Samuel Smith (1)
-
Samuel Stevens (1)
-
San Antonio Breast (54)
-
San Antonio Breast Cancer Sympos (67)
-
san antonio breast cancer symposium (1)
-
San Antonio Cancer Center (1)
-
San Camillo Forlanini Hospital (2)
-
San Raffaele Hospital (2)
-
Sandeep S. Arora (1)
-
Sandip Patel (1)
-
SANDPIPER (1)
-
Sandra Swain (1)
-
Sandra Wong (1)
-
Sandro Pignata (1)
-
Sandton Oncology Centre (1)
-
Sanjeev Arora (1)
-
SANTOSH RAO (1)
-
Santosshi Narayanan (1)
-
Saoussane Kharmoum (1)
-
Sapna Pradyuman Patel (1)
-
sar650984 (1)
-
Sara Christensen (1)
-
Sara Gafni (1)
-
Sara Hurvitz (3)
-
Sara Tolaney (2)
-
Sarah Bachmann (1)
-
Sarah Blair (1)
-
Sarah Brand (1)
-
Sarah Cannon Research Institute (2)
-
Sarah Goldberg (1)
-
Sarah Hoffe (1)
-
Sarah Holstein (3)
-
Sarah Hopkins (2)
-
Sarah Jackson (25)
-
Sarah Prinsloo (1)
-
Sarah Sammons (1)
-
Sarah Stream (1)
-
Sarah Weiss (1)
-
Sarah Yagerman (1)
-
Sarat Chandarlapaty (3)
-
sarcoma (2)
-
Sarcoma (3)
-
sarcomatoid (3)
-
sarcomatoid rcc (1)
-
sarcopenia (1)
-
Sarfraz Ahmad (1)
-
Sarina Isenberg (1)
-
Saro Armenian (1)
-
Satish Gopal (1)
-
Sattva Neelapu (1)
-
savolitinib (1)
-
SBRT (13)
-
scalp cooling (1)
-
SCALP trial (1)
-
SCLC (9)
-
score theory (1)
-
SCOT trial (1)
-
Scott Hamilton (1)
-
Scott Irwin (1)
-
Scott Kopetz (1)
-
SCOTT LITOW (1)
-
Scott Wilson (1)
-
screening (1)
-
screening eligibility (1)
-
Scripps Health (1)
-
Sean Smith (2)
-
Seattle Cancer Care Alliance (2)
-
Seattle Children’s Hospital (1)
-
Seattle Children's Hospital (1)
-
Sebastien Maury (2)
-
Sébastien Maury (1)
-
second cancer (1)
-
second cancers (1)
-
second opinions (1)
-
secondary cancers (1)
-
second-line therapy (4)
-
second-line treatment (3)
-
Sedan Dulgarian (1)
-
sedation (1)
-
Seema A. Khan (1)
-
Seema Bhat (2)
-
Seema Khan (2)
-
SEER database (2)
-
Sehn (1)
-
Seidman Cancer Center (1)
-
selecting treatment (1)
-
self-management (1)
-
Selina M. Luger (1)
-
Selma Schimmel (1)
-
semaphorin 4d (1)
-
seminoma (1)
-
sentinel nodes (1)
-
Seoul National U. Cancer Hospita (1)
-
Seoul National University Hospit (1)
-
Seppo Langer (1)
-
sequenced therapies (1)
-
sequencing agents (1)
-
sequencing therapy (4)
-
Sergey Kozhukhov (1)
-
Sergio Giralt (1)
-
serial (1)
-
serial care (1)
-
serious illness care (1)
-
serious ovarian cancer (1)
-
serous ovarian cancer (1)
-
serum cytokines (1)
-
serum-based biomarker (1)
-
Setting Tags (1)
-
sexual aids (1)
-
sexual function (2)
-
sexual gender minorities (1)
-
Shahrukh Hashmi (1)
-
Shailender Bhatia (2)
-
Shaji Kumar (5)
-
Shaker Dakhil (1)
-
Shakira Grant (3)
-
Shalmali Pal (13)
-
Shannon Coleman (1)
-
Shannon MacDonald (1)
-
Shannon Ugarte (2)
-
Shanta Boles (1)
-
Shanu Modi (2)
-
shared decision making (1)
-
Sharon Barger (1)
-
Sharon Berenfeld (1)
-
Sharon Donovan (1)
-
Sharyn Kurtz (1)
-
Shawn Amer (1)
-
Shawn Farrah (1)
-
Shawna Hudson (1)
-
Sheila Garland (1)
-
Sheila Leatherwood (1)
-
Sheila McGlown (1)
-
Sheila N. Garland (1)
-
Sheila Ross (1)
-
Shekinah Nefreteri Elmore (1)
-
Shelly Latte-Naor (5)
-
Sherene Loi (3)
-
Sheri Sobrato Brisson (1)
-
Sherri Rosenthal (1)
-
Shiao-Pei Weathers (1)
-
Shiliang Zhang (1)
-
Shilo Kramer (1)
-
Shira Klapper (1)
-
Shirlee Simpson (1)
-
Shirley Grandahl (1)
-
Shoshana Rosenberg (1)
-
Shou-Ching Tang (1)
-
Shradda Dalwadi (1)
-
Shreya Desai (1)
-
Shridar Genevan (1)
-
Shrinivas Rathod (1)
-
Shulian Wang (1)
-
Shumei Song (1)
-
Sian Pugh (1)
-
siblings (1)
-
Sibylle Loibl (3)
-
side effects (4)
-
Sideny Kimmel Cancer Center (1)
-
Sidney Kimmel Cancer Center (1)
-
Sidney Kimmel Comprehensive Canc (2)
-
Sidney Kimmel Comprehensive Cancer Center (1)
-
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University (1)
-
Sigrid Barklund (1)
-
Silvia Novello (2)
-
Silvio Monfardini (9)
-
Simon Cancer Center (1)
-
Simon Davies (1)
-
Simon Rule (2)
-
Simone Consulting Company (2)
-
Simone Koole (1)
-
Simron Singh (2)
-
Sincere McMillan (1)
-
Sindhuja Kadambi (1)
-
single fraction (1)
-
single-agent therapy (1)
-
single-dose radiotherapy (1)
-
single-gene test (1)
-
Sir Murray F. Brennan (2)
-
sirolimus (1)
-
SITC (22)
-
Siteman Cancer Center (1)
-
skeletal event (1)
-
skin cancer (25)
-
Skin Cancer (9)
-
skin toxicities (1)
-
sleep disturbances (1)
-
SLL (6)
-
SLNB-positive (1)
-
small cell lung cancer (10)
-
small lymphocytic leukemia (2)
-
small lymphocytic lymphoma (2)
-
small molecule inhibitors (1)
-
small-molecule inhibitor (1)
-
smart start (1)
-
smartphone app (1)
-
Smilow (1)
-
Smilow Cancer Hospital (3)
-
Smita Banerjee (1)
-
Smita Bhatia (4)
-
Smith Breast Center (1)
-
Smith Giri (1)
-
smoking (3)
-
smoking cessation (2)
-
smoldering myeloma (5)
-
So Yeon Kim (1)
-
social function (1)
-
soft tissue sarcoma (1)
-
SOFT trial (8)
-
soft-tissue sarcoma (2)
-
Sola Kim (1)
-
Solange Peters (2)
-
SOLAR trial (1)
-
SOLAR-1 (1)
-
solid cancers (1)
-
solid tumors (8)
-
Solid Tumors (4)
-
SOLO2 trial (2)
-
solo3 (1)
-
somatic mutation (1)
-
Somnath Mukherjee (2)
-
Sonali Smith (6)
-
Sonia Ray (1)
-
Sonja Vliek (1)
-
Sonja Zweegman (1)
-
Sophia Kustas Smith (1)
-
sophia trial (2)
-
sorafenib (10)
-
soritinib (1)
-
Sormain trial (1)
-
sotatercept (1)
-
South Texas Oncology and Hematology (1)
-
Southampton University Hospital (1)
-
Southwest Oncology Group (1)
-
spanish-speaking (1)
-
SPARTAN trial (1)
-
SPCG-13 trial (1)
-
sperm bank (1)
-
spinal cord compression (1)
-
spinal instability (1)
-
spinal lesions (1)
-
spinal metastases (1)
-
spleen (1)
-
splenectomy (1)
-
splenic volume (1)
-
splicing modulator (1)
-
sporadic breast cancer (1)
-
SPPORT trial (1)
-
squamous (2)
-
squamous carcinoma (1)
-
squamous cell (2)
-
squamous cell carcinoma (6)
-
squamous lung cancer (1)
-
squamous NCLC (2)
-
SQUIRE (1)
-
SQUIRE trial (2)
-
Srdan Verstovsek (1)
-
Srikala Sridhar (2)
-
Srinadh Komanduri (1)
-
Sriram Yennu (1)
-
St. Jude (2)
-
St. Jude Children's (1)
-
St. Jude Children's Research Hos (1)
-
St. Jude Family Advisory Council’s Subcommittee on Quality of Life and Palliative Care (1)
-
Stacey Berg (1)
-
Stacyann Bailey (1)
-
stage 4 (1)
-
stage data (1)
-
stage I (1)
-
stage I cancer (1)
-
stage I testicular cancer (1)
-
stage II (2)
-
stage II breast cancer (1)
-
stage III (1)
-
stage III breast cancer (1)
-
stage III cancer (1)
-
Stage III disease (1)
-
stage III melanoma (1)
-
stage IV disease (1)
-
stage IV lung cancer (2)
-
staging (1)
-
staging criteria (1)
-
staging quality (1)
-
STAMPEDE (1)
-
STAMPEDE trial (10)
-
Stan Winokur (2)
-
standard of care (2)
-
standard radiotherapy (1)
-
standard therapy (1)
-
Stanford (1)
-
Stanford Cancer Center (1)
-
Stanford Cancer Institute (5)
-
Stanford Health Care (1)
-
Stanford School of Medicine (1)
-
Stanford University (8)
-
Stanford University Medical Center (1)
-
Stanford University School of Me (1)
-
Stanley M. Marks (1)
-
STAR trial (1)
-
starting mammography age (1)
-
state of cancer care (3)
-
state of the art (1)
-
statins (1)
-
statistical analysis (1)
-
Stay With Me Awhile (1)
-
Stefan Ciurea (1)
-
Stefan Terwindt (1)
-
Stefano Signoroni (1)
-
stem cell transplant (2)
-
steml cell transplant (1)
-
step-care approach (1)
-
Stephan Stilgenbauer (4)
-
Stephanie Graff (2)
-
Stephanie Walker (1)
-
Stephen Ansell (5)
-
Stephen Chandler (1)
-
Stephen Chun (2)
-
Stephen Forman (2)
-
Stephen Fox (1)
-
Stephen Gottschalk (1)
-
Stephen Johnston (1)
-
Stephen R.D. Johnston (1)
-
Stephen Sagar (1)
-
Stephen Schuster (2)
-
Stephen Sonis (1)
-
step-wise guidance (1)
-
stereotactic (1)
-
stereotactic ablative radiation (3)
-
stereotactic body radiation ther (2)
-
stereotactic body radiotherapy (8)
-
stereotactic radiation (1)
-
Steven E. Vogl (6)
-
Steven Horwitz (4)
-
Steven Kalister (1)
-
Steven Le Gouill (2)
-
Steven Narod (1)
-
Steven Nurkin (1)
-
Steven Shak (1)
-
Steven Treon (1)
-
Steven Vogl (13)
-
stigma (1)
-
StiL trial (1)
-
STREAM (1)
-
strength training (1)
-
stress (2)
-
stress management (2)
-
stroma (1)
-
stromal tumor (1)
-
stromal tumor-infiltrating lymph (1)
-
structured reporting (1)
-
Stuart Lichtman (3)
-
Stuart M. Lichtman (12)
-
Subeera Khan (1)
-
subserosal (1)
-
substance use disorders (1)
-
subtypes (1)
-
SUCCESS A trial (1)
-
Sudhir Srivastava (2)
-
Sue Yom (1)
-
suffering (1)
-
suicide (3)
-
suicide ideation (1)
-
suicide risk (1)
-
Suleika Jaouad (1)
-
Sumanta Kumar Pal (1)
-
Sumanta Pal (11)
-
Sumit Agarwal (1)
-
Sumit Shah (1)
-
Suneel Kamath (1)
-
sunitinib (22)
-
sunitinib vaccine (1)
-
Sunnybrook Health Sciences Centr (1)
-
Sunnybrook Odette Cancer Centre (1)
-
support services (1)
-
supportive care (8)
-
Supportive Care (3)
-
Supriya Chopra (2)
-
Supriya Mohile (1)
-
Suresh Ramalingam (4)
-
Suresh S. Ramalingam (2)
-
surgery (6)
-
surgery volumes (1)
-
surgical cytoreduction (1)
-
surgical management (1)
-
surgical oncology (9)
-
surgical resection (1)
-
surgical site infection (1)
-
surgically resectable (1)
-
surgically resected patients (1)
-
surprise conversation (1)
-
surrogate endpoint (1)
-
survaxm (1)
-
surveillance testing (1)
-
survey (1)
-
surviellance therapy (1)
-
survival (7)
-
survival analysis (2)
-
survival in cancer (1)
-
survival rates (1)
-
survival registry (1)
-
survivin (1)
-
survivor (2)
-
survivorship (24)
-
Survivorship (3)
-
survivorship care (2)
-
survivorship provider (1)
-
survivorship standard (1)
-
survivorship-specific programs (1)
-
Susan Cohn (1)
-
Susan Falbo (1)
-
Susan Faye Dent (1)
-
Susan London (79)
-
Susan M. O’Brien (1)
-
Susan O’Brien (1)
-
Susan O'Brien (3)
-
Susan Reckling (23)
-
Susan Slovin (1)
-
Susan Swanson (1)
-
Susana Banerjee (1)
-
susceptibility (1)
-
Sushil Bhardwaj (1)
-
sustainable efforts (1)
-
Suzanna Zick (1)
-
Suzanne George (1)
-
Suzi Tortora (1)
-
Swedish Cancer Institute (1)
-
switch maintenance (1)
-
SWOG (3)
-
SWOG 0819 (1)
-
SWOG 1406 (1)
-
SWOG S0819 (1)
-
SWOG S0927 (1)
-
SWOG S1117 (1)
-
SWOG S9921 (1)
-
SWOG-8814 (1)
-
SWOGS0307 (1)
-
Syed (1)
-
Syed A. Abutalib (7)
-
Syed Abutalib (55)
-
Syed Ali Abutalib (68)
-
SYK/JAK (1)
-
Sylvester Comprehensive Cancer Center at the University of Miami (3)
-
Sylvie Leotin (1)
-
symptom assessment (1)
-
symptom burden (1)
-
symptom control (3)
-
symptom management (7)
-
Symptom Management (2)
-
symptom monitoring (1)
-
symptom reduction (1)
-
symptomatic relapse (2)
-
systemic chemotherapy (1)
-
systemic disease (1)
-
systemic therapy (5)
-
systemic treatment (1)
-
systems of care (1)
-
T cell (2)
-
T cells (5)
-
T. Ming Chu (1)
-
T1 tumors (1)
-
T1-2N0M0 (1)
-
T3 resectable cancer (1)
-
T790M mutation (1)
-
tags trial (1)
-
tailored therapy (1)
-
TAILORx (6)
-
Takeshi Kodaira (1)
-
Talal Hilal (1)
-
Talapro-2 (1)
-
talazoparib (1)
-
Talha Shaikh (1)
-
Tamim Niazi (1)
-
Tammie Denyse (1)
-
Tammy Schuler (2)
-
tamoxifen (16)
-
tamoxifen adherence (1)
-
Tamy Kim (2)
-
Tanya Dorff (1)
-
Tanya M. Wildes (1)
-
Tanya Spektor (1)
-
Tanya Wildes (1)
-
Taofeek Owonikoko (1)
-
tappas trial (1)
-
TAPUR (1)
-
Tara Henderson (2)
-
targeted agents (2)
-
targeted biologics (1)
-
targeted therapy (6)
-
targeted treatment (9)
-
targeted treatments (7)
-
taselisib (1)
-
Tata Memorial Centre (1)
-
Tata Memorial Hospital (2)
-
Tatiana Prowell (2)
-
Taussig Cancer Institute (1)
-
taxane (3)
-
taxol (1)
-
Taylor Bell Duck (1)
-
TBCRC 024 (1)
-
t-cell checkpoint (1)
-
T-cell therapy (1)
-
T-DM1 (5)
-
t-dxd (1)
-
TEAM IIb trial (1)
-
team management (1)
-
tecemotide (1)
-
technology (1)
-
tegafur (1)
-
telehealth (2)
-
telemedicine (1)
-
Temidayo Fadelu (1)
-
temozolomide (1)
-
temsirolimus (2)
-
Teresa Calimeri (2)
-
Teresa Pedersen (1)
-
terminal cancer (1)
-
Terri Coutee (1)
-
Terry Fry (1)
-
test (1)
-
testicular cancer (6)
-
testosterone suppression (1)
-
Texas A&M (1)
-
Texas Children's Hospital (1)
-
TEXT trial (2)
-
tgr-1202 (1)
-
TH3RESA trial (1)
-
Thaddeus Mason Pope (17)
-
The Angeles Clinic and Research (1)
-
The ASCO (1)
-
The ASCO Post (4155)
-
The ASCO Post Staff (5123)
-
The Christie NHS Foundation Trust (1)
-
the editors (1)
-
the mednet (1)
-
The Netherlands Cancer Institute (1)
-
The Ohio State University (5)
-
The Royal Marsden (2)
-
The Royal Marsden NHS Foundation (1)
-
The Royal Marsden NHS Foundation Trust (3)
-
The University of Chicago (1)
-
The University of Colorado (1)
-
The University of Manchester (2)
-
The University of Sydney (1)
-
The University of Texas MD Anderson Cancer Center (21)
-
The University of Texas Southwestern Medical Center (1)
-
The West Clinic (1)
-
Theodora Karnakis (1)
-
Theodore Lawrence (1)
-
Theodore Yaeger (1)
-
therapeutic response (1)
-
Therese Bevers (3)
-
Thierry Andre (1)
-
third generation inhibitors (1)
-
Thomas Abrams (1)
-
Thomas Buchholz (2)
-
Thomas D'Amico (2)
-
Thomas E. Witzig (1)
-
Thomas Goode (1)
-
Thomas J. Lynch Jr (1)
-
Thomas J. Roberts (1)
-
Thomas J. Smith (1)
-
Thomas Jefferson University Hosp (2)
-
Thomas LeBlanc (2)
-
Thomas Lester (1)
-
Thomas Powles (2)
-
Thomas Smith (1)
-
Thomas Stinchcombe (1)
-
thoracic cancer (2)
-
Thoracic Cancers Symposium (23)
-
thoracic malignancies (1)
-
thoracic radiation (1)
-
thoracic radiotherapy (1)
-
thoracic vertebral bodies (1)
-
thoracolaparoscopic (1)
-
thoracoscopic lobectomy (1)
-
thromboctyopenia (1)
-
thrombocythaemia (1)
-
thrombocytopenia (1)
-
thromboprophylaxis (2)
-
thrombosis (1)
-
thrombotic thrombocytopenic purp (1)
-
thymic epithelial tumors (1)
-
thyroid cancer (4)
-
Thyroid Cancer (1)
-
thyroid palpation (1)
-
Tia Higano (4)
-
Tiffany Fagnani (1)
-
Tiffany H. Williams (1)
-
TIGERx study (1)
-
TILs (3)
-
Tim Ahles (2)
-
TIM BARTHOLOW (1)
-
Tim Donald (2)
-
timely treatment (1)
-
Timothy Fenske (1)
-
Timothy Gilligan (2)
-
Timothy Murtha (1)
-
Timothy Quill (1)
-
Timothy S. Fenske (1)
-
Timothy Wilt (1)
-
Tina Marin (1)
-
Ting Bao (18)
-
tipiracil (1)
-
Tisch Cancer Institute (1)
-
titan trial (2)
-
tivo-3 trial (1)
-
tivozanib (1)
-
TK1 (1)
-
TK1 resistance (1)
-
TKI (7)
-
TKI resistance (1)
-
tkis (1)
-
tmb (1)
-
TNBC (13)
-
TNM staging (1)
-
TNT trial (2)
-
tobacco cessation (1)
-
Toby Campbell (1)
-
Todd Gibson (1)
-
Todd Palmby (1)
-
Todd Pickard (1)
-
Tom Baker Cancer Centre (1)
-
Tom Whitehead (1)
-
Tomma Hargraves (1)
-
Tommy Donbavand (1)
-
Toni Choueiri (16)
-
TONIC trial (1)
-
Tonie Forster (1)
-
Tony K.W. Hung (1)
-
Tony Mok (14)
-
Torben Plesner (2)
-
Tori Brunetti (1)
-
Toronto Sunnybrook Cancer Centre (1)
-
Toshihiko Doi (2)
-
total cancer care (1)
-
total neoadjuvant therapy (1)
-
toxicities (2)
-
toxicity (18)
-
toxicity burden (1)
-
Tracey Aiello (1)
-
Tracey Danaher (1)
-
Tracey Evans (1)
-
Tracy Balboni (1)
-
Tracy Batchelor (3)
-
trametinib (5)
-
transcend cll 004 (1)
-
TRANSCEND NHL 001 (1)
-
transitional cell carcinoma (1)
-
translational research (1)
-
transperineal radiation (1)
-
trastuzumab (18)
-
trastuzumab deruxtecan (2)
-
trastuzumab emtansine (4)
-
trastuzumab emtasine (1)
-
trastuzumab-resistant disease (1)
-
trasutuzmab (1)
-
Traver Hutchins (1)
-
trc105 (1)
-
treatment adherence (3)
-
treatment advances (1)
-
treatment burden (3)
-
treatment completion (1)
-
treatment deferment (1)
-
treatment deintensification (3)
-
treatment delays (1)
-
treatment disparities (1)
-
treatment duration (2)
-
treatment efficacy (1)
-
treatment errors (1)
-
treatment guidelines (1)
-
treatment intensification (1)
-
treatment modality (1)
-
treatment outcomes (2)
-
treatment paradigms (1)
-
treatment period (1)
-
treatment plan (1)
-
treatment plans (1)
-
treatment resistance (2)
-
treatment resistant (1)
-
treatment response (4)
-
treatment targets (1)
-
treatment toxicity (1)
-
treatment update (2)
-
treatment volume (2)
-
treatment-free remission (1)
-
treatment-naive (1)
-
treatment-naïve (4)
-
treatment-refractory (1)
-
tree nuts (1)
-
tremelimumab (1)
-
Trent Tipple (1)
-
trial enrollment (2)
-
trifluridine (1)
-
trigger (1)
-
trimodality therapy (1)
-
triple negative breast cancer (2)
-
triple-negative breast cancer (30)
-
triplet (1)
-
triplet regimen (1)
-
Tristana Vásquez (1)
-
TRK fusion (1)
-
tropomyosin receptor kinase inhi (1)
-
TRUS biopsy (1)
-
tucatinib (1)
-
Tulane (2)
-
Tulane Cancer Center (1)
-
Tulane University (1)
-
tumor biology (1)
-
tumor boards (1)
-
tumor complexity (1)
-
tumor gene expression (1)
-
tumor infiltrating lymphocyte (1)
-
tumor location (1)
-
tumor microenvironment (2)
-
tumor mutational burden (2)
-
tumor profiling (4)
-
tumor proportion score (3)
-
tumor response (1)
-
tumor sidedness (2)
-
tumor treating fields (1)
-
tumor-infiltrating lymphocytes (2)
-
tumors (1)
-
Tuya Pal (1)
-
Ty Higuchi (1)
-
Tycel Phillips (1)
-
Tyler Stewart (1)
-
tyrosine kinase inhibitor (11)
-
U Alabama at Birmingham (1)
-
U Alabama Cancer Center (1)
-
U Colorado Cancer Center (1)
-
U Colorado Health Science Center (1)
-
U Michigan Cancer Center (1)
-
UAB Comprehensive Cancer Center (1)
-
ublituximab (2)
-
UC Davis (1)
-
UC Irvine (2)
-
UC San Diego (4)
-
UC San Diego Moores (1)
-
UC San Francisco (6)
-
UCLA (12)
-
UCLA David Geffen School of Medicine (2)
-
UCLA Fielding School of Public Health (1)
-
UCLA Jonsson (3)
-
UCLA Medical Center (3)
-
UCSD (2)
-
UCSF (5)
-
UCSF Helen Diller (1)
-
Ugo Pastorino (2)
-
Ujwal Yanala (1)
-
ulcerative colitis (1)
-
ultra-high risk relapsed/refract (1)
-
ultrasensitive detection (1)
-
Umberto Vitolo (1)
-
Umbraco (1)
-
umbrella study (1)
-
Umea University Hospital (1)
-
UNC (3)
-
UNC Chapel Hill (4)
-
UNC health care (1)
-
UNC School of Medicine (1)
-
underserved (1)
-
underserved cancer patients (1)
-
underserved populations (1)
-
undertreatment (1)
-
unequal survival (1)
-
unilateral (1)
-
unilateral breast cancer (1)
-
Union for International Cancer Control (1)
-
UnitedHealth Group (1)
-
UnitedHealthCare (2)
-
Universitaetsklinikum des Saarla (1)
-
University Clinic of Navarra (3)
-
University College London (2)
-
University Hospital Basel (1)
-
University Hospital Erlangen (1)
-
University Hospital Essen (2)
-
University Hospital Heidelberg (1)
-
University Hospital Hôtel-Dieu (1)
-
University Hospital Leuven (1)
-
University Hospital of Lille (2)
-
University Hospital Zurich (1)
-
University Hospitals Gasthuisber (1)
-
University Hospitals Leuven (3)
-
University Medical Center Gronin (1)
-
University of Alabama at Birming (2)
-
University of Alabama Birmingham (4)
-
University of Alberta (1)
-
University of Amsterdam (1)
-
University of Arizona (1)
-
University of Athens (1)
-
University of Barcelona (2)
-
University of Basel (1)
-
University of British Columbia (5)
-
University of Calgary (1)
-
University of California (2)
-
University of California Irvine (1)
-
University of California San Die (2)
-
University of California San Francisco (3)
-
University of Cambridge (1)
-
University of Chicago (11)
-
University of Colorado (3)
-
University of Colorado at Denver (1)
-
University of Colorado Cancer Ce (1)
-
University of Edinburgh (1)
-
University of Florida (1)
-
University of Gothenburg (1)
-
University of Greifswald (2)
-
University of Illinois Chicago (1)
-
University of Iowa Carver College of Medicine (1)
-
University of Iowa Hospital (1)
-
University of Kentucky (1)
-
University of Lausanne (2)
-
University of Leeds (2)
-
University of Liverpool (1)
-
University of Manitoba (1)
-
University of Maryland (1)
-
University of Maryland Medical C (1)
-
University of Maryland Medical Center (1)
-
University of Memphis (1)
-
University of Miami Health Syste (1)
-
University of Michigan (8)
-
University of Michigan Health Sy (2)
-
University of Milan (1)
-
University of Minnesota (3)
-
University of Montreal (2)
-
University of Nantes (1)
-
University of Nebraska (7)
-
University of Nebraska Medical (5)
-
University of Nebraska Medical C (7)
-
University of Nebraska Medical Center (3)
-
University of New Mexico (2)
-
University of New South Wales (1)
-
University of North Carolina (16)
-
University of North Carolina Lineberger Comprehensive Cancer Center (1)
-
University of Paris Sud (1)
-
University of Pennsylvania (12)
-
University of Pittsburgh (2)
-
University of Queensland (1)
-
University of Rochester (1)
-
University of Rochester Medical Center (1)
-
University of San Diego (1)
-
University of South Carolina (1)
-
University of Southampton (3)
-
University of Southern Californi (1)
-
University of Sydney (3)
-
University of Texas (1)
-
University of Texas MD Anderson (1)
-
University of Torino (4)
-
University of Toronto (1)
-
University of Tubingen (2)
-
University of Tuebingen (2)
-
University of Turin (1)
-
University of Ulm (1)
-
University of Warwick (1)
-
University of Washington (10)
-
University of Washington Seattle (1)
-
University of Wisconsin (6)
-
University of Wisconsin Carbone (2)
-
University Paris Descartes (1)
-
University Paris-Sud (1)
-
UNMC (3)
-
unrelated HCT (1)
-
unresectable (2)
-
unresectable bladder cancer (1)
-
unresectable disease (1)
-
untreated RCC (1)
-
upfront surgery (1)
-
upfront therapy (1)
-
upfront treatment (1)
-
UPMC Hillman Cancer Center (1)
-
upper gastrointestinal cancer (1)
-
upstaging (1)
-
Uqba Khan (1)
-
uracil (1)
-
urban setting (1)
-
urethral cancer (1)
-
urinary tract cancer (1)
-
urogenital cancers (1)
-
urologic surgery (1)
-
Uroosa Ibrahim (1)
-
urothelial (1)
-
urothelial cancer (12)
-
urothelial carcinoma (11)
-
Ursula A. Matulonis (3)
-
Ursula Matulonis (3)
-
Ursula Sansom-Daly (2)
-
US Food and Drug Administration (2)
-
US Intergroup (1)
-
US Preventive Services Task Forc (1)
-
USC (3)
-
USC Norris (4)
-
USC Norris Cancer Center (4)
-
USC Norris Comprehensive Cancer Center (1)
-
Usha Menon (1)
-
usual care (1)
-
UT Health (1)
-
UT Health San Antonio Cancer Center (1)
-
UT Health Science Center (1)
-
UT Southwestern Medical Center (2)
-
uterine cancer (1)
-
UTSW (1)
-
UV exposure (2)
-
vaccine (3)
-
vacuum-assisted (1)
-
vadastuximab talirine (2)
-
Vadim Gushchin (1)
-
Vaishali Sanchorawala (1)
-
Vali Papadimitradopoulou (1)
-
Vali Papadimitrakopoulou (2)
-
Valisia LeKae (1)
-
Vall d'Hebron University Hospita (2)
-
value (2)
-
value in cancer care (3)
-
value in medicine (1)
-
value-based care (2)
-
Vamsidhar Velcheti (2)
-
Vanderbilt (1)
-
Vanderbilt Ingram (3)
-
Vanderbilt University (5)
-
Vanessa Eaton (1)
-
vaping (1)
-
variation in quality (1)
-
Vassiliki Papadimitrakopoulou (2)
-
VEGF (1)
-
VEGF blockade (1)
-
VEGF inhibitor (1)
-
Vejle Hospital (1)
-
velia/cog-3005 (1)
-
Velindre Hospital (1)
-
veliparib (7)
-
velipatib (1)
-
vemurafenib (3)
-
venetoclax (8)
-
venetoclax monotherapy (1)
-
venous thromboembolism (4)
-
Vered Stearns (3)
-
VHL (1)
-
Vicki Jackson (2)
-
Vicki Morrison (1)
-
Victor Vogel (2)
-
video tool (1)
-
vigil (1)
-
VIJAYA RAJ BHATT (1)
-
Vinay Prasad (1)
-
vinblastine (2)
-
Vincent DeVita (1)
-
Vincent Rajkumar (1)
-
vincristine (2)
-
vinflunine (3)
-
Vinicius Ernani (1)
-
vinorelbine (2)
-
viral reactivation (1)
-
Virginia Anderson (2)
-
Virginia Commonwealth University (1)
-
Virginia Kaklamani (1)
-
Vishal Bhatnagar (1)
-
Visionary Leader Award (1)
-
vitamin D (2)
-
Vivek Agarwala (1)
-
Viviane Hess (1)
-
VOLKER DIEHL (1)
-
vomiting (3)
-
Von-Hippel Lindau (1)
-
vorinostat (2)
-
Vratislav Strnad (1)
-
VTE (3)
-
vulvar cancer (2)
-
W. Marston Linehan (1)
-
W. Robert Lee (3)
-
Wafik El-Deiry (1)
-
Waldenström’s (1)
-
Waldenström’s Macroglobulinemia (1)
-
Walter Curran Jr (1)
-
Warren Mason (1)
-
Warwick Medical School (1)
-
Washington University (2)
-
Washington University School of Medicine in St. Louis (1)
-
watch and wait (1)
-
Watson for Oncology (1)
-
Wayne Kuznar (2)
-
wbi (1)
-
WBRT (3)
-
WCLC 2015 (24)
-
wealth expenditure (1)
-
wearable sensors (1)
-
web-based intervention (1)
-
web-based tool (1)
-
weight loss (4)
-
weight-based doses (1)
-
weight-loss intervention (1)
-
Weijing Sun (1)
-
Weill Cornell Medical College (2)
-
well follow-up (1)
-
well tolerated (1)
-
Wendy Demark-Wahnefried (1)
-
Wendy Harpham (2)
-
Wendy Lichtenthal (3)
-
Wendy Selig (1)
-
Wendy Vogel (5)
-
Wendy Wing-Lok Chan (1)
-
West Cancer Center (3)
-
West Clinic (1)
-
WHI (1)
-
white blood cell growth factor t (1)
-
white patients (2)
-
who (1)
-
WHO classification (1)
-
whole brain radiation (1)
-
whole brain radiotherapy (1)
-
whole breast radiation therapy (3)
-
whole exome sequencing (2)
-
whole genome profiling (1)
-
whole-brain radiotherapy (1)
-
whole-breast irradiation (1)
-
wild type (1)
-
wild-type (2)
-
wild-type KRAS (1)
-
William Aronson (1)
-
William Breitbart (12)
-
William Catalona (1)
-
William Curry (3)
-
William Dale (1)
-
William Gradishar (7)
-
William H. Redd (1)
-
William H. Sharfman (1)
-
William Hall (1)
-
William J.M. Hrushesky (1)
-
William M. Grady (1)
-
william m. sikov (2)
-
William McGivney (2)
-
William Meyer (1)
-
William N. Harwin (1)
-
WILLIAM OH (1)
-
William S. Shimp (3)
-
William Sikov (3)
-
William Tew (1)
-
William Travis (2)
-
William Wierda (3)
-
Wilms tumor (2)
-
Winship Cancer Institute (3)
-
Wolfgang Wick (1)
-
women (2)
-
Women and Infants Hospital of Rh (1)
-
women cancer survivors (1)
-
women in oncology (2)
-
Women Who Conquer Cancer (2)
-
Women's Health Initiative (2)
-
Women's Health Initiative Dietar (1)
-
workflow (1)
-
workforce development (1)
-
workplace stress (1)
-
workshop (1)
-
World Health Organization (1)
-
Wui-Jin Koh (2)
-
WUSTL (1)
-
www.reimagine.me (1)
-
Wyndham H. Wilson (1)
-
Wyndham Wilson (2)
-
Xin Gao (1)
-
Xin Zheng (1)
-
Xuesong Han (1)
-
Y537S mutation (1)
-
Yale Cancer Center (9)
-
Yale Law (17)
-
Yale School of Medicine (3)
-
Yale School of Nursing (1)
-
Yale University (2)
-
Yale University School of Medicine (1)
-
YANIN CHAVARRI-GUERRA (1)
-
Yen Nien (Jason) Hou (6)
-
Yen Nien Hou (5)
-
Yesne Alici (1)
-
Ying Taur (1)
-
yoga (1)
-
Yoli Origel (1)
-
Yonsei Cancer Center (1)
-
Yoon-Koo Kang (2)
-
young adult cancer (3)
-
young adult cancer survivor (1)
-
young adult oncology (2)
-
young adults (2)
-
young breast cancer (1)
-
young breast cancer patients (1)
-
young breast patients (1)
-
young cancer patients (1)
-
young patients (2)
-
young patients at end of life (1)
-
young women (1)
-
younger patients (3)
-
Yousuf Zafar (1)
-
Yulia Raskina (1)
-
Yung-Jue Bang (1)
-
Z. Kevin Liu (1)
-
Z11 study (1)
-
Zaina Qureshi (3)
-
Zelenetz (1)
-
Zeynep Zengin (1)
-
Zhongxing Liao (2)
-
Zineb Benbrahim (1)
-
ZINEB DAHBI (1)
-
Zofia Piotrowska (1)
-
zoledronic acid (1)
-
ZUMA-1 (1)
-
ZUMA-1 trial (1)